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Dedicated to Outi.
‘I have not failed. I’ve just found 10,000 ways that won’t work.’
- Thomas Edison-
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ABSTRACT
Unverricht-Lundborg type progressive myoclonus epilepsy (EPM1, OMIM 254800) 
is an autosomal recessive disorder characterized by onset at the age of 6 to 16 years, 
incapacitating stimulus-sensitive myoclonus and tonic-clonic epileptic seizures. It is 
caused by mutations in the gene encoding cystatin B (CSTB). However, the disease 
processes leading to the observed symptoms are currently unclear. Clinical magnetic 
resonance imaging (MRI) of the brain has shown neurodegenerative changes and 
computed tomography data have suggested a bone phenotype. This thesis examined 
the disease processes and the background of the pathological changes in the brain 
and the bone, utilizing modern imaging methods and image analysis methodology 
complemented with experimental data in the mouse model (the Cstb -/- mouse) of 
the disease.  
In order to gain a comprehensive picture of the disease progression in the brain, we 
performed a longitudinal imaging study in the Cstb -/- mouse. Animals were studied 
from the pre-symptomatic to fully symptomatic disease stages (1-6 mo). For studying 
atrophic changes, in vivo MRI volumetry was preformed once a month from 1 to 
6 months of age. For investigating white matter (WM) changes, ex vivo diffusion 
tensor imaging (DTI) was performed at 2, 4 and 6 months. The fractional anisotropy 
(FA) maps derived from DTI data were analysed using track based spatial statistics 
(TBSS) that provided us with a hypothesis-free analysis of white matter changes. In 
vivo volumetry showed progressive volume loss in Cstb-/- mice over time, the rate of 
which was neither spatially nor temporally uniform over the brain. TBSS revealed 
progressing FA decrease, suggesting severe and widespread WM damage, with most 
drastic changes in the cerebellum and the thalamus.
Subsequently the congruence of the observed WM changes between the mouse 
model and EPM1 patients were evaluated. In vivo DTI data from fully symptomatic 
adult patients and ex vivo data from fully symptomatic (6 mo) Cstb-/- mice were 
analysed using TBSS with matching protocols. The results revealed extensive 
changes with a pattern of chronic WM degeneration in EPM1 patients, with similar 
alterations detected in Cstb-/- mice. Furthermore, previously unknown brain regions 
were shown to be affected both in patients and in mice. The imaging data were then 
used to guide tissue level analyses in mice. The microstructural counterpart of the 
areas with decreased FA in mice was characterized by immunohistochemistry and 
transmission electron microscopy. Based on the tissue level findings, the extensive 
changes identified by DTI in both EPM1 patients and in Cstb-/- mice are probably a 
consequence of widespread WM loss upon axonal degeneration, and likely contribute 
to the motor disturbances present in the disease. 
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Finally, we characterized the bone changes underlying the observed skeletal 
phenotype in EPM1 patients by performing microtomography (µCT), histology, 
and in vitro cell culture experiments with the Cstb-/- mouse. Analysis of bone 
microstructure in Cstb-/- mice using µCT revealed structural changes. Moreover, 
histology confirmed both structural and functional alterations. The basis of these 
findings was investigated by studying the functionality of bone resorbing osteoclasts 
differentiated in vitro from bone marrow. In resorption pit formation assays, less 
and smaller resorption pits were formed by Cstb-/- osteoclasts, indicating decreased 
resorptive capacity, likely due to a decrease in osteoclast numbers. These data imply 
that the skeletal changes in Cstb-/- mice and EPM1 patients are a result of CSTB 
deficiency leading to altered osteoclast function, and the results would indicate that 
CSTB has a more substantial role as a modulator of bone metabolism than previously 
thought. 
Our results showed high correlations of the atrophy, WM and bone phenotypes 
between EPM1 patients and Cstb-/- mice and provided information about brain 
and tissue level changes present in these pathologies. High correlation between the 
mouse model and the findings in patients provided further affirmation for the use of 
the mouse model in EPM1 research. Furthermore, the results provided new insight 
both into the progression of brain pathology and the processes underlying the bone 
changes present in the disease. Finally, our research introduced new methodologies 
for research in mouse models of neurodegenerative diseases, and raised the prospects 
of future research. 
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TIIVISTELMÄ
Etenevä myoklonusepilepsia (Unverricht-Lundborgin tauti, EPM1) on suomalai-
seen tautiperimään kuuluva, autosomaalisesti peittyvästi periytyvä sairaus, jonka en-
simmäiset oireet havaitaan 6–15 vuoden iässä. Ensimmäiset oireet ovat useimmiten 
ulkoisten ärsykkeiden laukaisemia lihasnykäyksiä tai epileptisiä kohtauksia. EPM1 
aiheutuu virheistä kystatiini B (CSTB)-proteiinia koodaavassa geenissä ja vaikka 
taudin aiheuttava geenivirhe on selvitetty, oireisiin johtavat tautimekanismit ovat 
edelleen tuntemattomat. Kliininen magneettikuvantaminen on osoittanut potilaiden 
aivoissa harmaan aineen vauriota ja tilavuudenalenemaa ja tietokonekerroskuvauk-
sessa potilailla on havaittu kallon luiden paksuuntumista. Tässä väitöskirjatyössä 
pyrittiin kartoittamaan EPM1:n etenemistä ja havaittujen muutosten aikaansaavia 
kudos- ja solutason muutoksia käyttäen moderneja kuvantamis- ja kuvankäsitte-
lymenetelmiä sekä histologiaa ja soluviljelykokeita taudin kystatiini B puutteisessa 
(Cstb -/- hiiri) hiirimallissa.
Taudin etenemistä aivoissa selvitettiin suorittamalla pitkittäisseurantaa taudin 
hiirimallissa. Kuvantaminen aloitettiin oireettomissa hiirissä, ja seurantaa jatkettiin 
kaikkien taudinkuvaan kuuluvien oireiden ilmenemiseen asti (1–6 kk). EPM1:ssä 
esiintyvän tilavuudenaleneman etenemistä tutkittiin in vivo magneettikuvantamisella, 
ja valkean aineen muutoksia ex vivo diffuusiotensorikuvamisella. Käyttäen hypotee-
sivapaata vokselipohjaista analyysimenetelmää (Track based spatial statistic, TBSS) 
valkean aineen muutoksia seurattiin analysoimalla fraktionaalisen anisotrofian (FA) 
muutoksia. Havaitsimme Cstb -/- hiirissä etenevän  tilavuudenaleneman, jonka määrä 
vaihteli eri aivoalueiden välillä. Diffuusiotensorikuvantaminen  osoitti etenevään 
aivokudoksen vaurioon viittaavan FA aleneman, joka ilmeni voimakkaimmin tala-
muksissa ja pikkuaivossa.
Seuraavaksi kartoittamme havaittujen valkean aineen vaurioiden yhtenevyyttä 
hiirimallissa ja potilaissa. Aikuisten EPM1 potilaiden in vivo ja aikuisten Cstb -/-(6kk) 
hiirten ex vivo diffuusiotensorikuvantamisdata analysoitiin käyttäen identtisiä TBSS- 
protokollia. Tulokset osoittivat laaja-alaisia, krooniseen rappeumaan viittaavia valkean 
aineen muutoksia EPM1-potilaissa, ja hiirimallissa havaittiin vastaavat muutokset. 
Analyysi paljasti sekä potilaissa, että Cstb -/- hiirissä muutoksia aivoalueilla, joiden ei 
ole aikaisemmin tiedetty EPM1:ssä vaurioituneen. Havaittujen muutosten alkuperää 
tutkittiin Cstb -/- hiirissä kudostason tarkastelulla soluleikkeistä immunohistokemial-
lisin värjäyksin, ja elektronimikroskooppisella analyysillä. Tulokset osoittivat että sekä 
EPM1 potilaissa että hiirimallissa diffuusiokuvantamisella havaitut valkean aineen 
muutokset ovat seurausta aksonikadosta, ja ovat todennäköisesti yhteydessä taudissa 
esiintyviin liikehäiriöihin. 
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EPM1-potilailla havaittujen luumuutosten taustoja selvitettiin Cstb -/- hiirissä 
tietokonekerrokuvauksella (microtomography; µCT), kudosleikevärjäyksillä ja solu-
viljelykokein. Tietokonekerroskuvaus osoitti luun hienorakenteen muuttuneen Cstb 
-/- hiirissä, minkä lisäksi kudosleikevärjäyksissä todettiin  luussa sekä rakenteellisia 
että toiminnallisia muutoksia. Näiden muutosten alkuperää kartoitettiin luuta kier-
rättävien osteoklastien soluviljelykokein. Kun solujen kykyä hajottaa luuta tutkittiin, 
havaittiin Cstb -/- hiirten osteoklastien muodostavan vähemmän ja pienempiä resorp-
tiivisia kuoppia. Tämä kertoo osteoklastien heikommasta hajotuskyvystä, ja muutos 
Cstb -/- hiirissä on todennäköisesti seurausta matalammasta solumäärästä viljelmissä. 
Vaikuttaa siltä, että sekä EPM1 potilaissa, että taudin hiirimallissa havaitut luumuu-
tokset ovat seurasta kystatiini B puutteen aiheuttamista muutoksista osteoklastien 
toiminnassa. Nämä tulokset viittaavat siihen, että kystatiini B:llä on aikaisempaa 
suurempi rooli luun metabolian säätelyssä.
Tutkimustuloksemme hiirissä vastasivat potilaissa havaittua aivojen  tilavuudenale-
nemaa, valkean aineen vaurioita ja luulöydöksiä, ja pystyimme osoittamaan niihin 
johtavat kudos- ja solutason muutokset. Havaintomme valottavat EPM1:n huonosti 
tunnettua etenevää taudinkuvaa, sekä ennestään tunnettujen muutosten taustaa, ja 
löydösten yhteneväisyys hiirimallissa ja potilaissa rohkaisee EPM1-tutkimuksen 
jatkamista Cstb -/- hiirimallissa. Väitöskirjatutkimus esitteli   myös uusia  menetel-
miä aivorappeumatautien hiirimallitutkimuksessa sekä avasi uusia tutkimusalueita 
EPM1:n taudinkuvan selvittämisessä. 
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1 INTRODUCTION
“En usko ennen kuin näen.”
Old Finnish proverb
We perceive the world around us predominantly through our vision, and as the 
above proverb states, things are often believed only after they have been seen. 
For observing things too far away to see with the naked eye, we use binoculars or 
even telescopes. For things that are too small to see otherwise, we use magnifying 
glasses or microscopes. Events or details that would not otherwise be observable 
can be witnessed with the aid of different imaging methods. Occurrences too fast to 
perceive as they happen can be visualised in slow motion, and extremely slow changes 
become clear in time-lapse. Similarly, thermography cameras visualises differences 
in temperatures and x-ray imaging allows us to see through and inside things. 
In observational sciences, such as astronomy, observing the surroundings gives the 
scientist an opportunity to gain information on what has happened or is happening, 
however the researcher does not interact with or manipulate the events. In experimental 
research the scientific method is utilized for acquiring new knowledge. Based on 
previous knowledge and reasoning, a hypothesis is formulated and experiments testing 
the hypothesis are conducted. Once the outcome of the experiment is observed, results 
can be analysed and based on the results, a hypothesis is confirmed or re-evaluated. 
In experimental sciences, observing the outcome of the experiment is commonly 
observed visually. Combined with the scientific method, our yearning for visual proof 
constantly transforms the worldview by delivering new insight into the universe and 
its inner workings. In this thesis, modern imaging methods were combined with the 
experimental hypotheses and the approach was able to provide new insights into 
previously unknown pathological processes in a disease.
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REVIEW OF THE LITERATURE
1.1 MACRO- AND MICROANATOMICAL BASIS OF THE 
STUDY SUBJECT
1.1.2 Cellular organisation of the brain
“I am a brain, Watson. The rest of me is a mere appendix.” 
Arthur Conan Doyle, Sherlock Holmes - The Adventure of the Mazarin Stone
Due to its paramount function and structural complexity, the organisation of 
the mammalian brain has been extensively studied (Cowan, Harter & Kandel 
2000). The neuronal doctrine, or the theory that the nervous system consists of 
individual interconnected cells, neurons, is considered the groundwork for modern 
neuroscience. It was first described by Santiago Ramón y Cajal (Llinas 2003), and for 
this groundbreaking discovery he was awarded the Nobel Prize in medicine (Nobel 
Lectures Physiology or Medicine 1901–1921). The following description of the 
composition and basic organisation of the brain (Figure 1) has been adapted from 
a description given by Purves et al (Purves 2012). The basic building block of the 
central nervous system (CNS) is a neuron, an excitable cell that is highly specialized 
in the transmission and processing of signals through electric and chemical means. 
Multiple neurons connect to each other to form neuronal networks that transmit 
signals in the brain. While there are multiple neuron types that vary in structure 
and function, their basic organisation is the same. Neurons consist of a main body 
called the soma, extensions of the soma called dendrites that receive signals into the 
neuron, and axons, cable like projections to that transmit signals to other neurons 
through synapses. The signal transmission in axons happens through small electric 
signals generated through changes in cell membrane potential along the axons. As 
the axons project over long distances, the insulating myelin sheath surrounding the 
axon ensures fast and efficient signal transduction. Neurons connect to each other 
through synapses, special neuron-to-neuron connections that allow transmission of 
signals from one cell to another. The signal transmission from one cell to another 
usually happens through the synaptic cleft with the aid of neurotransmitters, signal 
transmission molecules stored in synaptic vesicles in the axon side of the synapse. 
These neurotransmitters are released into the synaptic cleft from the pre-synaptic 
side, and bind to receptors on the postsynaptic side. In some cases signal transmission 
occurs directly through electric signalling from cell to cell.
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A gross histological division between brain regions predominantly containing 
cell bodies of neurons or axons into respective grey and white matter is commonly 
used. The axon-dense part of the brain tissue, that is rich in myelinated axons and 
oligodendroglia, is called white matter, due to the historical fact that formalin fixed 
tissue has a light, almost white appearance as a result of its high myelin content. 
Regions that contain predominantly neuropil, meaning soma, dendrites, astroglia, 
microglia and unmyelinated axons, are referred to as grey matter. This is due to the 
noticeably darker appearance in formalin fixed brain tissue. The function of the white 
matter is to relay signals between different regions of brain, where they are processed 
in the neurons located in the grey matter. Due to the communicative function of the 
white matter, deterioration in its functional integrity has drastic consequences. In for 
instance multiple sclerosis (MS) (Mallucci et al. 2015, Criste, Trapp & Dutta 2014) 
and leukodystrophy (Groeschel et al. 2012), demyelination is known to produce a 
wide range of motor, sensory and psychiatric symptoms. 
While neurons have historically been considered the predominant cell type in the 
brain, they are aided in their task to a great degree by the neuroglial cells. The glia do 
not directly take part in signal transmission, but rather have a supportive function. 
The glial cells were primarily considered a to be an unimportant filler or merely 
structural cells in the brain, hence the Greek name meaning ‘glue’ (Baumann, Pham-
Dinh 2001). While more and more the tasks of the glial cells are still discovered, 
they currently are known to play important roles in aiding neurons in the formation 
and maintenance of neuronal circuits, and they have been identified to play a role 
in insulating axons, maintaining the ionic balance of the extracellular space and 
supporting synaptic transmission (Allen, Barres 2009). Oligodendroglial cells are 
responsible for ensheathing axons in layers of myelin, and maintaining these layers 
to ensure efficient signal transduction. Astroglia get the their name from their star 
like shape, and function to provide regulation of the extracellular space by removing 
excess ions and recycling neurotransmitters, and thus maintaining an environment 
suitable for the transmission of signals. Microglia, a specific type of glial cell, are the 
resident immune response unit in the CNS that scan the brain for injury or infection 
and remove pathogens, dead cells and debris via phagocytosis. While activation of 
microglia is observed in most neuropathological conditions, the role of microglia in 
the disease processes of CNS disorders is still debated (Prinz, Mildner 2011, Allen, 
Barres 2009). 
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Figure 1. Central cell types in the nervous system. The diagram illustrates central celltypes 
in the brain and their interactions. Shown are astroglia (purple), neurons (grey), microglia 
(yellow) and oligodentroglia (green). Different parts of the neuron have also been marked in 
the image. 
The described fundamental cellular configuration forms the functional circuitry 
of the brain, with individual structures forming distinguishable functional and 
anatomical units with dedicated tasks. The layout and the function of the brain 
regions most relevant to the subject matter of this thesis, the thalamocortical system 
and the cerebellum, is reviewed in detail in following chapters.
1.1.3 Thalamocortical system
The thalamic nuclei are responsible for conveying signals between different subcortical 
areas and the cortex, and this signal relay consisting of the cerebral cortices, the 
thalamus and their connecting fibres is referred to as the thalamocortical system 
or the thalamocortical relay. The cortices are responsible for the higher cognitive 
tasks and have dedicated motor, sensory and cognitive areas with distinct functions 
located in their respective areas. The sensory information is received by the primary 
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sensory cortical areas and the output of the primary motor cortex is to the spinal cord 
while the higher order sensory and motor areas integrate and process information. 
All the different regions, however, share a six-layered (referred to as layers I–VI) 
organisation. Each layer consists of its own characteristic cell types, function and 
connections with distinct contribution to the neuronal processing. Layer I consists 
mainly of laterally linked axons that connect different cortical regions, while layers 
II and III are mostly responsible for output over different cortical areas. The neurons 
in layer IV receive input from the thalamus and are responsible for distributing it 
to other cortical layers. Finally, layers V and VI receive information from the cortex 
and relay it to the thalamus, basal ganglia, brain stem and spinal cord. 
The thalamus has a paramount impact in the cortical processes as a hub that most 
of the cortical information travels through. It is situated between the cerebellum and 
the midbrain, and it is composed of individual nuclei that are connected to their 
respective cortical regions. The information received by thalamic nuclei from sensory 
pathways and subcortical regions (and from layer V from cortical regions excluding 
the originating relay site) is conveyed to cortical layer IV, where it is spread to other 
layers. The corticothalamic fibres running from layer V provide afferent projections 
from the cortex to the thalamus, and some modulatory signals are also received from 
layer VI (Figure 2).  While the thalamo-cortico-thalamic circuit is incompletely 
understood, it is known have a synchronising function, a filtering task to the cortical 
inputs and integrating information, as well as an executive role of timing and relaying 
cortical output. Besides the relay function, the thalamus is also thought to contribute 
to processing of sensory information and is known to have a role in verbal, motor and 
sensory memory (Purves 2012). A recent review concluded that the thalamococortical 
and corticothalamic networks that participate in governing sleep and consciousness 
contribute to the observed alterations in the state of consciousness in absence 
epilepsies (Bagshaw et al. 2014) and a voxel based morphometry (VBM) study in 
juvenile myoclonic epilepsy and idiopatic generalized epilepsy patients reported 
decreased functional thalamocortical connectivity contributing to the symptoms 
(Kim et al. 2014). Clinical studies have also demonstrated that thalamic lesions lead 
to ataxia (Solomon et al. 1994, Melo et al. 1992) and an imaging study investigating 
deep brain stimulation also showed involvement of the cerebello-thalamo-cortical 
network in the control of tremor and myoclonic tremor (Coenen et al. 2014).
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Figure 2. Simplified diagram of thalamocortical connectivity. The diagram illustrates 
corticothalamic, thalamocortical and corticocortical connectivity with arrows illustrating 
signalling directions. The layered structure of the cortex is also illustrated.
1.1.4 Cerebellum
The cerebellum is located at the base of the skull and consists of gyri: folded layers 
of cortex, covering white matter that surround a grey matter structure called deep 
cerebellar nuclei (Figure 3). Due to it’s small size and appearance that parallels the 
cereberal cortices, the Latin  ‘cerebellum’ translates as ‘little brain’ (Butts, Green & 
Wingate 2014). While the cerebellum is known have a role in cognitive functions, 
language, attention and regulating fear responses, its most important tasks are in 
motor control (Wolf, Rapoport & Schweizer 2009). The cerebellum itself does not 
govern movement, but it ensures that various motor systems act in unison to produce 
intended action by providing accuracy, timing and coordination to movements that 
require a high degree of synchronization.  
The layout of the cerebellum is highly symmetrical with 10 lobules, with each 
lobule consisting of a matching set of neuronal elements with a laminated cerebellar 
cortex, and grey matter structures called central deep cerebellar nuclei that are located 
at the centre of the cerebellar white matter. The deep cerebellar nuclei are hubs of 
cerebellar information transfer and almost all output fibres from the cerebellum 
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originate from there. The deep cerebellar nuclei receive excitatory input from mossy 
fibres and climbing fibre pathways and inhibitory input from Purkinje cells. On a 
larger scale, the cerebral cortex receives information from the cerebellum through 
the thalamus, and sends it to the cerebellum via the pons. The aim of this system is 
to detect discrepancies between planned action, and actual performed movements, 
and rectify motor errors. While errors in movement are corrected in real time, these 
corrections are also stored and form the foundation of motor learning (Purves 2012) 
and according to a review by Fine, Ionita and Lohr, the cerebellum to also has a role 
in cognitive functions such as verbal fluency, abstract reasoning, planning, intonation 
of speech and the correct use of grammar (Fine, Ionita & Lohr 2002). Furthermore, 
a recent review also concluded cerebellum to have a role in emotional processing 
in fear and motor responses to emotion (Strata 2015), and speech and non-motor 
language function (Marien et al. 2014).
As the cerebellum itself does not initiate or govern movement, the disorders of 
the cerebellar function do not as such manifest as absence or excess of movement and 
are instead commonly observed as deficits in the management of motor function. In 
a patient with a focal thalamic lesion, the role of cortico-cerebellar interactions in 
motor error prediction was demonstrated by investigating impairment in adaptive eye 
saccades (Zimmermann et al. 2015)and in a study investigating psychomotor function 
in patients with cerebellar lesions, inadequate hand-eye coordination highlighted 
the corrective role of the cerebellum in producing intended movement, as well as 
a cerebellar role in visual function (Sailer, Eggert & Straube 2005). A diffusion 
weighted imaging (DWI) study of traumatic brain injury patients demonstrated 
a decrease in cerebellar functional connectivity that corresponded with inadequate 
balance and postural control (Drijkoningen et al. 2014). A VBM study coined 
progressing cerebellar atrophy with deteriorating motor function in spinocerebellar 
ataxia (Mascalchi et al. 2014) and a functional magnetic resonance imaging (fMRI) 
study with a rhythmic the finger-tapping task in patients with tremor demonstrated 
alterations in cerebellar motor output (Buijink et al. 2015), illustrating the cerebellar 
role in limiting undesired movement and the impairments in motor performance 
that manifest when this task is incompetently performed.
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Figure 3. Immunohistogical staining of mouse cerebellum. Immunohistological staining 
against myelin proteolopid protein (brown colour) in a sagittal cerebellar tissue section illustrates 
the white matter under the gyrous cortical surface of the cerebellum.
1.1.5 Principles of bone remodelling
All vertebrates have an endoskeleton, commonly referred to as the skeleton, that 
offers protection and support for the internal organs, and enables locomotion for the 
organism by providing support and leverage as well points of contact for muscles. This 
skeleton consists of various types of connective tissue: ligament, tendon, cartilage, 
and most importantly, bone. The following description of bone, and it’s remodelling 
has been adapted from a book by Currey (Currey 2013).
Bone is seen in a multitude of shapes and sizes, and bone tissue consists two 
distinct bone types, stiff and tough cortical bone and light and porous trabecular 
bone. The cortical bone forms the hard exterior of the bones, while the inside consists 
of light and porous trabecular bone which provides support and helps distribute 
the forces subjected to the cortical bone. While these two components differ in 
microstructure and mechanical properties, they share the same principal arrangement. 
Bone is structurally a composite of two major components. The mineral calcium 
phosphate provides mechanical strength and stiffness to the bone, and the organic 
collagen matrix supports the structure and provides elasticity and fracture resistance 
to the tissue. Bones are also known act as reserve for calsium, and trabecular bone 
contains bone marrow, which is responsible for haematopoiesis.
Due to its role of in locomotion, bone is constantly under mechanical stress and 
requires maintenance and repair, as well as remodelling. This is a dynamic process, 
24   
in which old bone is digested and new bone formed. Bone is digested by osteoclasts, 
multinucleated cells rich in lysosomes. They are of monocyte origin and are formed 
through fusion of pre-osteoclasts. The osteoclasts attach to surface of the bone and 
form a sealing zone at the periphery of the cell, which creates a lumen between 
the osteoclast and the bone into which the bone digesting enzymes are secreted to. 
Osteoclasts digest the bone by breaking down the collagen matrix with collagenases, 
most prominently cathepsin K (Cat K) and dissolving the mineral component of 
the bone. Bone is synthesised by cells at the surface of the bone called osteoblasts. 
The formation of new bone happens in a two stages. First, the osteoblasts secrete the 
organic component of the bone matrix, called osteoid, consisting predominantly of 
collagen I. Following this the osteoid is mineralised with help of alkaline phosphatases, 
creating mineralized bone. Osteoblasts that are no longer at the surface of the 
bone, become incorporated in the bone and turn into osteocytes, cells responsible 
of maintaining bone homeostasis. Disturbances in the homeostasis of the bone 
formation and resorption lead to pathologic changes in bone composition, such as 
osteopetrosis (Boyce et al. 2014), or osteoporosis (McGowan et al. 2014)
1.2 PROGRESSIVE MYOCLONUS EPILEPSY, EPM1
“People think that epilepsy is divine simply because they don’t have any idea what 
causes epilepsy. But I believe that someday we will understand what causes epilepsy, 
and at that moment, we will cease to believe that it’s divine. And so it is with 
everything in the universe.”
-Hippocrates-
The brain is mechanically shielded from external insults by the skull, and meninges, 
as well as cushioned by the cerebrospinal fluid. It is also biologically protected by the 
blood-brain barrier and the immune system. Still, owing to the extreme complexity 
of the brain and the delicate biological balance needed to maintain its normal 
function, very small changes, such as defective function of a single cell type or lack 
of a single protein, can disrupt its equilibrium. 
One of the most devastating neurological disorders is epilepsy, a group of 
neurological disorders characterised by a common symptom of epileptic seizures 
that can vary in type, severity, length, rate of reoccurrence, origin and cause (Berg et 
al. 2010, Purves 2012). The seizures are a result of abnormal and excessive neuronal 
activity in the brain following genetic, metabolic or structural changes in the brain 
and different epilepsy types vary in type and cause of seizures. The presentation of 
the seizure types varies, ranging from partial to generalized, and seizures can have 
motor, sensory and psychological manifestations (Berg et al. 2010).  A variety of 
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causes for epilepsy are known, and the classification relies on the causative factors, 
with a division between acquired epilepsies and epilepsies with a genetic cause 
(Table 1) (Shorvon 2011). Tumours, traumatic brain injury, stroke or infections 
are a few examples of the numerous structural and metabolic changes in the brain 
known to cause epilepsies (Berg et al. 2010). Genetic causes for epilepsies vary from 
monogenic changes, to disorders known to result from multi-gene predisposition that 
environmental factors may also contribute to (Noebels 2015). Progressive myoclonic 
epilepsies (PME) are a group of rare epilepsy syndromes that are caused by a range of 
genetic defects (Berkovic, So & Andermann 1991). In PMEs, such as Lafora disease 
or Batten disease, an identified genetic cause translates into a lack or deficiency in 
protein expression, which in turn causes neurodegeneration that manifests as epileptic 
seizures, among other symptoms and pathologies (Minassian 2014). An identified 
genetic defect that translates into epilepsy through neurodegeneration also underlies 
a PME type called progressive myoclonic epilepsy type 1 (EPM1), the pathological 
processes of which this thesis investigates (Pennacchio et al. 1996) (Table1). 
In 1891, Heinrich Unverricht described a syndrome of progressive myoclonus 
epilepsy in patients of Baltic origin (Unverricht 1891, Unverricht 1895) and Herman 
Bernhard Lundborg reported the hereditary pattern of the similar syndrome in 
a Swedish family at the turn of the century (Lundborg 1912, Lundborg 1903). 
Based on the Baltic origin of the patients, the disease was first known as Baltic 
epilepsy, or Baltic myoclonic epilepsy, with a similar syndrome with patients from 
Mediterranean countries known as Mediterranean myoclonus. These were considered 
to be different syndromes, based on differences in onset and severity, however they 
were later confirmed to be the same disease (Malafosse et al. 1992). Recognizing 
the research of Unverricht and Lundborg, the syndrome is known as Unverricht-
Lundborg disease, however the name EPM1 (OMIM254800) is also used. EPM1 
is considered part of the Finnish disease heritage, a group of rare genetic disorders 
enriched in the Finnish population due to founder effects and genetic isolation 
(Norio 2003). The disease is recessively inherited, and its incidence in Finland is 
1 in 20 000 births (Norio, Koskiniemi 1979). It is also part of the group of PME 
disorders, characterised by their common features of progressive neurological decline, 
myoclonus and epilepsy, with EPM1 the single most common cause for PME. Other 
diseases classified as PMEs include type I sialidosis, myoclonus epilepsy and ragged 
red fibres (MERRF syndrome), Lafora disease and neuronal ceroid lipofuscinoses 
(Berkovic, So & Andermann 1991). EPM1 is considered underdiagnosed around 
the world due to its rare nature, need for genetic diagnosis and symptoms that are 
reminiscent of other PMEs and juvenile myoclonic epilepsy (Kälviäinen et al. 2008, 
de Haan et al. 2004).
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Table 1. The etiological classification of epilepsies adapted from Shorvon (2011) (Shorvon 2011)
Main category: Subcategories:
Idiopathic epilepsy Pure epilepsies due to single gene disorders
Pure epilepsies with complex inheritance
Symptomatic epilepsy: Predominately 
genetic or developmental causation
Childhood epilepsy syndromes
Progressive myoclonic epilepsies (EPM1)
Neurocutaneous syndromes
Other neurologic single gene disorders
Disorders of chromosome function
Developmental anomalies of cerebral 
structure
Symptomatic epilepsy: Predominately 
acquired causation
Hippocampal sclerosis





Cerebral immunologic disorders 
Degenerative and other neurologic 
conditions
Provoked epilepsy Varied provoking factors
Reflex epilepsies
Cryptogenic epilepsies
1.2.1 Clinical presentation and course of the disease
The onset of EPM1 is typically between 6 to 16 years of age and the manifesting 
symptoms are most often tonic-clonic epileptic seizures or stimulus sensitive 
involuntary myoclonic jerks, provoked by action, lights or sound (Koskiniemi et al. 
1974, Norio, Koskiniemi 1979). As the disease advances, other symptoms including 
ataxia, incoordination, intentional tremor, and dysarthria emerge (Kälviäinen et al. 
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2008). The myoclonus becomes more severe and the clinical state of the patients 
declines for 5-10 years, before the disease progression stabilizes (Magaudda et al. 
2006). The epileptic seizures can be controlled with anti-epileptic drugs, namely 
valproic acid, clonazepam, piracetam, levetiracetam, topiramate and zonisamide 
(Kälviäinen et al. 2008, Roivainen, Karvonen & Puumala 2014), however the 
myoclonus and ataxia present in the disease remains resistant to the treatment47. 
Thus, the mainstay of EPM1 treatment is continuing psychological and rehabilitive 
support to the patients throughout their life, combined with anticonvulsant 
medication (Kälviäinen et al. 2008). The severity of the symptoms varies, with some 
patients rendered wheelchair bound by the severe ataxia and myoclonus while other 
remain virtually asymptomatic. With appropriate treatment, the life expectancy of 
the patients is approximately normal (Kälviäinen et al. 2008).
1.2.2 Neuropathological findings in EPM1 patients
Neuropathological data on EPM1 are scarce, and the available findings are 
heterogeneous. Part of this can be attributed to the deleterious effect of the previous 
phenytoin therapy, which is known to cause extensive cerebellar atrophy in the 
patients (Eldridge et al. 1983). The patients show loss of cerebellar granular cells and 
Purkinje cells (Eldridge et al. 1983)as well as neuron loss in the cortices, striatum, 
thalamus and brainstem (Mascalchi et al. 2002, Koskenkorva et al. 2009, Cohen et 
al. 2011, Koskiniemi et al. 1974)with changes also reported in spinal motor neurons 
(Eldridge et al. 1983). Imaging studies in EPM1 have demonstrated a range of 
changes in the brain. At the onset of the disease, patient MRI does not show any 
abnormalities, and changes become evident once the disease progresses (Kälviäinen 
et al. 2008). Most studies report cerebral atrophy and cerebral cortices are shown to 
undergo atrophy on sensory, motor and somatosensory regions (Koskenkorva et al. 
2012, Koskenkorva et al. 2009, Mascalchi et al. 2002). The severity of the myoclonus 
in patients has been shown to correlate with the cortical thinning present in the 
disease (Koskenkorva et al. 2012), and the changes in dopaminergic function are 
thought to contribute to the severely incapacitating myoclonus present in the disease 
(Korja et al. 2007b, Danner et al. 2013, Mervaala et al. 1986). Combined with the 
reported striatal and thalamic (Korja et al. 2007b) changes, the myoclonus and 
motor disturbances present in the patients have been considered to be of cortical 
origin (Koskenkorva et al. 2009) and augmented by the damaged thalamocortical 
circuitry (Suoranta et al. 2013).
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1.2.3 Bone findings in EPM1 patients
Besides the neurological pathologies, diffuse thickening of the skull and scoliosis 
(Koskiniemi et al. 1974) and more specifically hyperostosis frontalis interna (Korja 
et al. 2007a) have been reported in EPM1 patients. In line with the findings skull 
thickening, a transcranial magnetic stimulation study reported the distance from scalp 
to cortex to be longer in EPM1 patients (Danner et al. 2013). A study involving 66 
EPM1 patients showed that all patients exhibit diffuse thickening of cranial bones, 
with 61% also showing other skeletal changes, most commonly arachnodactaly, 
scoliosis, enlarged sinuses, and accessory ossicles of the foot (Suoranta et al. 2012). 
The underlying cause for diverse bone changes found in EPM1 patients is currently 
unknown.
1.2.4 Cystatin B (CSTB)
Recessive mutations of the cystatin B (CSTB) gene underlie EPM1 (Pennacchio 
et al. 1996), however, how these defects precicely lead to the observed symptoms is 
currently unclear. Presently, 14 causative expansion mutations have been identified 
(Pennacchio et al. 1996, Pinto et al. 2012, Lalioti et al. 1997, Joensuu, Lehesjoki 
& Kopra 2008). No genotype-phenotype correlation is known to exist, however 
compound heterozygote patients suffer from a more severe disease phenotype 
(Koskenkorva et al. 2011). The CSTB gene encodes protein cystatin B (CSTB, 
sometimes also referred to as stefin B) (Pennacchio et al. 1996, Ritonja, Machleidt 
& Barrett 1985), an inhibitor of lysosomal cysteine cathepsins, including cathepsin 
H, L, S, B and K (Green et al. 1984, Bromme, Rinne & Kirschke 1991). As Cat K 
has an vital role in bone resorption by osteoclasts (Kiviranta et al. 2005), inadequate 
inhibition of cat K could possibly play a part in the bone changes observed in 
patients. CSTB is known to be ubiquitously expressed in a variety of cell types 
and tissues, and has been shown to be expressed both in neurons and glial cells 
(Kominami et al. 1984, Okuneva et al. 2015).  Kindling induced status epilepticus 
has also been shown to upregulate Cstb expression in rats (D’Amato et al. 2000). 
1.2.5 Mouse model of EPM1
Due to the highly preserved nature of basic neuronal structure, much of neuroscientific 
research is conducted with model organisms. The nematode Caenorhabditis elegans 
is frequently used in the modelling and study of the nervous system due to its 
simple and thoroughly documented neuronal architecture and well known neuron 
development and connectivity (Sasakura et al. 2013). Fruit flies (Drosophilae 
melanogaster) are used due to the easy production of genetically modified models 
and their clearly identifiable phenotypes and are thus used as a model organism in 
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basic research of gene and protein function (Bellen, Tong & Tsuda 2010). Zebra 
fish (Danio rerio) are often used as a behavioral model due to their easily observable 
and quantifiable developmental behaviors and as a developmental model, as their 
embryonic development is rapid and easily observable (Clay, Coughlin 2015). 
At the other end of the spectrum of model organisms are non-human primates, 
such as rhesus macaques, which are utilised due to their extremely similar genetic 
background and brain structure as humans, up to the point that even enables studies 
on evolution of language (Fisher, Marcus 2006).
 In this thesis work, as very often in neuroscience, the model organism of choice 
is the mouse (Mus musculus). The genome of mice can be genetically modified to 
provide models of human disease through altering the expression of existing genes 
by silencing or over-expressing them or by introducing new genes into the genome. 
Mice also reproduce rapidly and their anatomy, genome and cell biology has been 
extensively studied (Harper 2010). Mice share 97% of their genome with that of 
humans and as a mammalian model, the mouse brain structure is very compatible for 
research in neuroscience (Harper 2010). Therefore they are extensively used in the 
study of diseases such as Alzheimer’s (Lau et al. 2008), Parkinson’s (Morin, Jourdain 
& Di Paolo 2014), and epilepsy (Harward, McNamara 2014), among many other 
neurological disorders (Nguyen, Xu 2008, Harper 2010). Nevertheless, due to the 
difference between the species in genetics, neuroanatomy and neurobiology, they 
never as such reproduce the complete phenotype of any human disorder (Morrissette 
et al. 2009, Harper 2010)and are, per se, only a model for studying disease processes.
After the underlying gene for EPM1 was identified, a knock-out mouse model 
(the Cstb-/- mice) for the disease was generated (Pennacchio et al. 1998). The model 
was generated by disrupting the reading frame of the mouse Cstb gene with an 
insertion of a neomysin cassette into the first exon, leading to an almost complete 
loss of the Cstb protein (Pennacchio et al. 1998). The mouse model has been shown to 
recapitulate the patient phenotype well, with myoclonus manifesting at the age of one 
month and ataxia emerging at the age of six months (Pennacchio et al. 1998). Unlike 
the stimulus sensitive myoclonus in patients (Kälviäinen et al. 2008), myoclonus in 
mice only manifests during sleep (Pennacchio et al. 1998), and can be so robust that 
it causes the animals to jump into the air (personal observation). 
The model replicates the cerebellar and cerebral atrophy as well as the loss of 
cerebellar granule cells and neurons observed in patients (Shannon et al. 2002, 
Pennacchio et al. 1998, Tegelberg et al. 2012). Atrophy and selective neuron loss have 
been shown to affect the thalamocortical system, hippocampus and entorhinal cortex, 
with loss of cortical neurons preceding the changes in the corresponding thalamic 
nuclei (Shannon et al. 2002, Tegelberg et al. 2012). The atrophy and volume loss in 
the cortex and cerebellum are progressive (Tegelberg et al. 2012) and the brain of the 
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mice is smaller compared to controls (Figure 4). The brain weighs approximately 25% 
less compared to controls, although no difference in the brain/body weight ratio is 
observed (Shannon et al. 2002). Histology in the Cstb–/– mouse has shown extensive 
gliosis, especially in the WM (Shannon et al. 2002)and gene expression analysis 
indicates upregulation of glial activation genes in 8-month-old animals (Lieuallen et 
al. 2001). At 1 month, increased expression of immune and defence response genes 
is also observed ( Joensuu et al. 2014). These findings are in line with the early and 
spreading microglial activation, seen already at p14, which precedes the astroglial 
activation, neuron loss and myoclonus that manifest in the early stages of the disease 
(Tegelberg et al. 2012). The cultured microglia demonstrate higher expression of Cstb 
mRNA compared to astroglia and neurons, and CSTB deficiency has been linked to 
altered function of microglia in the Cstb-/- mice (Okuneva et al. 2015). 
 
Figure 4. Cstb-/- mice are used as an EPM1 model in the study of the disease. EPM1 
mouse model recapitulates well the clinical symptoms seen in patients, with the onset of ataxia 
at 1 month and myoclonus at 6 months of age. The atrophy seen in the patients manifests also 
in the animal model and the picture illustrates the degree of volume loss in Cstb-/- brain at 6 
months, with a brain from a healthy control on the left, and a Cstb-/- brain on the right. One 
square represents 1 cm2. Picture by Saara Tegelberg.
The hippocampus of a Cstb–/– mouse shows latent hyperexcitability, likely due to loss 
of GABAergic inhibition (Buzzi et al. 2012, Franceschetti et al. 2007). Changes 
in GABAergic signalling pathways can already be observed at early stages of the 
disease, and in immunohistochemistry, Cstb-/- mouse neurons show less GABAergic 
terminals compared to controls ( Joensuu et al. 2014). This is likely to contribute to 
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the observed hyperexcitable phenotype, as histopathology from an EPM1 patient 
shows similar results (Buzzi et al. 2012). Histology and cell cultures have indicated 
that oxidative stress plays a role in the pathogenesis (Lehtinen et al. 2009). Altered 
tryptophan metabolism has also been reported in Cstb-/- mice (Vaarmann, Kaasik 
& Zharkovsky 2006), however the principal disease cascade leading to the observed 
pathological changes remains to be elucidated.
1.3 BASICS IN BIOLOGICAL IMAGING 
“If the hand be held between the discharge-tube and the screen, the darker shadow 
of  the bones is seen within the slightly dark shadow-image of the hand itself...                
For brevity’s sake I shall use the expression ‘rays’; and to distinguish them from others of 
this name I shall call them ‘X-rays’.” 
- Wilhelm Röntgen-
In biological research, visualization of the different structural or functional properties 
of organisms is essential. Biological imaging is an umbrella term that refers to 
methods used in visualising different aspects of biological systems. The oldest, and 
still most widely used biological imaging method is light microscopy, based on the 
use of visible light and magnifying lenses. It enables the study of structures too small 
to view with a naked eye, facilitating for instance the discovery of cells by Robert 
Hooke in 1665 (Hooke 1665). The value of biological imaging methods in research 
has been readily appreciated, with the first Nobel price in physics given to Wilhelm 
Röntgen for the discovery of x-rays and their use in imaging (Nobel Lectures Physics 
1901–1921). Biological imaging methods often start as tools for research, but find 
their way into medical applications, as rapidly happened with Röntgen’s invention, 
and subsequently, with many other imaging modalities.
Currently, a range of biological imaging methods is used in neuroscience in both 
clinical work and research. Cranial ultrasound is often used to study the brain of 
neonates as the the open sutures of the skull allow good penetrance for the sound 
waves, and this approach has been for instance used in investigating brain damage 
in preterm babies (Plaisier et al. 2015). Through the use of radioisotopes, positron 
emission tomography provides information concerning brain function through 
metabolic indications such as mapping hypoactivity of different brain regions in 
epileptic patients through their respective local glucose consumption (Akman et al. 
2015). 
32   
Magnetic resonance imaging (MRI) is a widely used imaging method that is based 
on nuclear magnetic resonance (NMR) as it can provide anatomical information, 
such as the imaging of tumors (Castillo 2014), or functional information on brain 
activity in functional MRI, or (fMRI) through changes in local haemodynamics 
for instance in investigating language centres in the brain (Gelinas et al. 2014). 
Magnetic resonance spectroscopy (MRS) can provide metabolic information using a 
MRI system, such as determining GABA concentrations in the thalamus of juvenile 
myoclonic epilepsy patients (Hattingen et al. 2014). Beside the use of x-ray imaging 
in investigating bone, like MRI, x-ray computed tomography (CT) is widely used in 
anatomical neuroimaging due to its versatility, and due to high anatomical resolution 
and the speed of acquisition it is for instance utilized in imaging of acute trauma 
cases (Semelka et al. 2007) and investigation of vasculature (Ravindra et al. 2015). 
Functional information can be obtained in optical imaging, such as observing the 
neurovasculature and blood oxidation for mapping seizure foci in neonates (Singh 
et al. 2014). Magnetoencephalography (MEG) is based on detecting magnetic fields 
produced by electric signals in the brain and can for instance be utilized in mapping 
cortical inhibitory activity (Danner et al. 2013). In this thesis, in addition to light 
microscopy, other imaging modalities, such as MRI, CT, and electron microscopy, 
were utilized. Their basic principles and applications will be described in more detail 
in the following chapters.
1.3.1 Principles of magnetic resonance imaging
Magnetic resonance imaging, or MRI, is a widely used medical imaging method that 
is based on NMR. It can provide anatomical, functional or metabolic information 
about the target tissue. Due to the extensive electromagnetic and quantum mechanical 
theoretical background behind the method, the basis of MRI and NMR is not 
usually explained to the full extent of the theory and is rather described with a 
simplified portrayal. The description given here has been adapted from the portrayal 
originally given by Gadian (Gadian 1995).
MRI is most commonly centred on observing hydrogen protons (1H) based on 
two physical properties of the atoms, their electrical charge, and their quantum 
mechanical property of spin, which can be described as angular rotary momentum 
of the particle against its axis. According to the law of physics, electrical charge in 
motion creates a magnetic field, and thus the nuclear spins could be visualized as 
small spinning bar magnets. As a quantum mechanical property, the spin values 
are not continuous and rather they can only have defined values.  Therefore, when 
placed in an external magnetic field, a molecule with a spin number ½ can align itself 
in one of two states. One is the low energy state of the spin, with the positive pole 
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aligned against the negative in the field, and the other, a high-energy state in which 
the positive nuclear pole faces the field.
Thus the nuclear magnet (the spin), when placed in an external magnetic field, 
can switch from its low energy state to its high-energy state by absorbing energy 
from a photon. Correspondingly, switching from high to low energy state emits a 
photon of equal energy. This switching of spin states is called transition, and it can 
be induced with an electromagnetic pulse of radiowave frequency. Thus, when the 
spins in a magnetic field are subject to a radio frequency pulse of correct frequency, 
the energy states of these spins change. This results, depending on the original state 
of the spins, in both absorption and emission of photons. The resonance frequency 
is called the Larmour-frequency and it is unique for each nuclei and strength of the 
external magnetic field.
If the number of spins in the high and low energy states would be equal, the 
number of emitted and absorbed photons after a transition would also be equal and 
no change in overall magnetisation would be observed. Due to the small energy 
difference between the low and high states the difference in spin populations is 
miniscule, one in ten thousand spins. The difference is still enough to yield a change 
in overall energy during transition, and can be observed with a radio frequency coil 
when the system returns towards equilibrium. The population difference is directly 
proportional to the magnetic field strength, and the amount of signal depends on 
the numbers of protons on the excited area. Thus the observed area must be large 
enough and contain enough protons to create a measurable signal.
In order to observe complex three-dimensional structures with MRI, the signal 
originating from different points in space along three axes has to be differentiated. In 
a magnetic field with a field gradient, protons in different regions along the gradient 
are subject to different field strengths. Since the resonance frequency of the protons 
depends on the strength of the magnetic field, the resonance frequency of the protons 
also depends on the position of the protons along the field gradient. Thus, a radio 
frequency pulse on specific frequency excites only a specific portioning of protons 
along the gradient. The signal is thus received from a specific area along the gradient 
and provides spatial resolution along one axis, which here shall be addressed as axis Z.
After the imaging slice direction on the Z-axis has been exited using a radio 
frequency pulse, the nuclei in that specific plane resonate on a frequency specific to 
the field strength (Larmour frequency) in common phase. If the protons in the plane 
are then subjected to a field gradient in a direction of the X-axis, the spins start to 
rotate with a resonance frequency corresponding to their position on the X-axis. 
When the field gradient on the X-axis is turned off and magnetisation returns, all the 
resonating spins rotate at same frequency, but in a different phase, which corresponds 
with their localisation along the X-axis. Therefore, localisation of the spins along the 
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X-axis can be determined by observing the phase of the spins. This is called phase 
encoding. Finally the plane is subjected to a field gradient along the Y-axis, so that a 
difference in the frequency of the spins along this axis is acquired, and technique for 
determining the source of the signal along the in three-dimensional space is achieved. 
A two-dimensional image is composed of pixels, but MRI is usually utilized for 
studying three-dimensional structures, in which images consist of pixels, that also 
contain volume information, or “voxels”. These represent a certain volume of the 
tissue or structure that is studied and represent the amount of signal acquired with a 
radio frequency coil from this volume. The signal is most commonly acquired from 
protons that are present in tissue water, fats or other hydrogen rich compounds. After 
excitation with radiofrequency pulse, the protons revert back to their original state 
in a process called relaxation. Each tissue type is characterized by their individual 
relaxation times for both longitudinal relaxation (T1), and transverse relaxation 
(T2) and the use of imaging sequences sensitive to these relaxation times provide a 
way to discern wide range of tissues. Images in which main source of the contrast is 
from T1 relaxation are called T1-weighted, and ones with predominantly T2 based 
signal are referred to as T2-weighted. Use of sequence that minimize the effect of 
differences in T1 and T2 times produces an image in which the contrast is based on 
the proton density of the tissue. These are called proton density weighted images. The 
acquisition process of signal from tissue involves intricate manipulation of magnetic 
fields and radio frequency pulses and reconstructing the images requires elaborate 
signal processing, but these are based on the principles described here.
MRI has wide range of applications, and is routinely used in clinical and research 
settings, in which MRI systems are commonly utilized for obtaining anatomical 
information. Examples of these uses include pre-surgical investigation of lesions 
in epilepsy surgery patients (Holthausen, Pieper & Kudernatsch 2013) or tumours 
(Castillo 2014). Using an MRI system, MRS can also be performed for acquiring 
metabolic information about tissues, such as obtaining information about cortical 
N-acetyl-aspartate levels in NCL patients (Worgall et al. 2007). Information about 
brain activity can be obtained in fMRI by following changes in local blood flow 
and oxidation and this method can be used for instance in pre-operatic mapping of 
hemispheric language dominance in epilepsy surgery patients (Gelinas et al. 2014). 
Use of interventional MRI is also emerging with operations like MRI navigated 
transurethral prostate cancer treatments (Ghai, Trachtenberg 2015). A widely used 
MRI method called diffusion weighted imaging provides information the about 
movement of water in tissue and its principles and uses are described in more detail 
in the following chapter.
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1.3.2 Diffusion weighted imaging
Acquiring information on the diffusion of molecules, usually water, in tissue using an 
MRI system is called diffusion weighted imaging (DWI). The explanation of DWI 
and its principles given here have been adapted from the portrayal originally given 
by Mori (Mori 2007). Water molecules in tissue are in constant movement due to 
Brownian motion, and an MRI system can be used to acquire signal from protons in 
water. In brief, diffusion information is acquired by using a pulse to dephase the spins 
in the area of image acquisition, after which a time for diffusion of water is allowed. 
Before acquiring the signal, a rephasing pulse is used to rephase the spins in the area 
of acquisition. In a scenario where no diffusion of water has happened, all the spins 
are rephased and the same total amount of signal is acquired. Diffusion causes some 
of the water that could have been re-phased move out of the plane, leading to signal 
attenuation. Loss of signal is proportional to the amount of diffusion happening in 
the plane. This provides information about the diffusion in one direction along the 
phase-encoded axis, meaning that the measurement must be repeated for all three 
gradient directions to obtain three-dimensional diffusion information, which can 
be used for instance in calculating average diffusivity per voxel. 
DWI is commonly utilised for obtaining information about tissue microstructure 
that affects the diffusion characteristics of water. From data acquired using DWI, 
representations of diffusion in tissue can be calculated. This information is often 
presented in the form of tensor, leading to the common use of term diffusion tensor 
imaging (DTI). For calculating diffusion tensors, diffusion information from at least 6 
directions is required. In the tensor model, the diffusion of water in three-dimensional 
space is represented with three orthogonal tensors: lambda 1, lambda 2, and lambda 3. 
Common DTI parameters calculated from these tensors include the diffusion along 
the main axis of diffusion, referred to as axial diffusion (AD), diffusion on the plane 
parallel to the main axis, referred to as radial diffusion (RD) and a calculated mean 
of these two, mean diffusivity (MD). Anisotropy of diffusion indicates how variable 
the diffusion is in different directions and is commonly represented by the parameter 
fractional anisotropy (FA). It is a scalar value, calculated out of DTI data, and can 
range from 0 for isotropic, unrestricted/equally restricted to 1, for to anisotropic, or 
totally restricted to all but one direction (Figure 5). Pathological processes in the 
brain often cause rapid changes in local diffusion dynamics, which makes DTI a 
sensitive and acute way of obtaining information about the affected tissue. Since 
water diffuses more freely parallel to axons than perpendicular to them, FA is a robust 
indicator of pathological processes. It can easily be compared between subjects and 
is commonly used as a marker of WM integrity (Liu et al. 2011, Burzynska et al. 
2010, Damoiseaux et al. 2009) as decreased FA combined with increase of RD (and 
possible decreased AD) is observed with loss of fibre or demyelination  (Concha et 
36   
al. 2006, Sun et al. 2008). This is thought to result from increase in axonal spacing 
(Sen, Basser 2005). To name few examples, DTI has been used in study of white 
matter abnormalities in focal epilepsy patients (Campos et al. 2015), investigating 
WM integrity in ischemic stroke patients (Dacosta-Aguayo et al. 2014) and WM 
changes in Alzheimer’s (Li et al. 2015), among many other uses. DTI is also used 
in animal models of neurodegenerative disease, and has been used for instance to 
investigate the progression of WM changes in traumatic brain injury in rats (Begonia 
et al. 2014), following neonatal hippocampal lesions in macaques (Meng et al. 2014) 
and assessing myelin damage in a mouse model of spinal cord injury (Tu et al. 2013).
Figure 5. Fractional anisotropy reflects restrictions of diffusion due to tissue micro-
structure. Fractional anisotropy reflects the effect of tissue microstructure on the diffusion of 
water in tissue. When the diffusion of water is not restricted in any direction, this accounts for 
isotropic diffusion, whereas tissue microstructure, such as axon bundles in white matter restrict 
diffusion of water in certain directions, which causes highly restricted diffusion that is reflected 
by high fractional anisotropy.
1.3.3 Track-based spatial statistics
Analysing complex three-dimensional datasets, such as whole brain FA data, is 
very labour-intensive when done manually. This often leads to the restriction of 
analysed areas and the use of a region of interest (ROI) based approach. In such 
cases the research hypothesis dictates which areas are analysed. Restricting the areas 
of analysis based on the hypothesis however overlooks changes in areas previously 
unknown or not assumed to be affected. Reproducible and bias-free ROI selection 
in different sized or atrophied subjects also requires a high degree of anatomical 
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expertise. This has prompted the need for automated analysis of 3D imaging data. 
One such method in brain imaging is tract-based spatial statistics (TBSS) analysis 
(Smith et al. 2006, Smith et al. 2007). In this method, all whole brain FA-maps 
that are compared are brought into a common 3D-space for voxel by voxel group 
level statistical comparison of FA-values. In the method the FA-maps of brains 
are cross-compared to find the most representative brain of the groups, in order 
to minimize the need for warping individual brains when brought into a common 
3D space. The most representative brain is then selected to be used as a template, 
into which the rest of the FA-maps are co-registered to using affine and non-linear 
transformations. This representation of the whole brain is then averaged into a mean 
FA image of the whole group. As the WM tracts have high FA-values, by setting 
a threshold the FA-values the mean brain can be used to form an FA-skeleton 
representing the major WM-tracts. All analysed brains are skeletonized with the 
same threshold. After this, all individual FA-skeletons are aligned to the template 
using affine transformations and centers of the WM-tracts are co-aligned on the 
template skeleton. As all the FA-maps have been brought to a common 3D-space 
and the WM-tracts aligned, FA-values of each voxel can be statistically compared. 
The method can be also used for analysing other measures of diffusion, AD, RD 
or MD, to complement the FA analysis. AD indicates diffusion in the primary 
direction of diffusion, RD the diffusion along the two minor directions and MD 
indicates mean diffusion of all directions combined.
As TBSS is a group level analysis method, it has only limited clinical diagnostic use. 
However, in research settings it has been demonstrated to be effective in identifying 
WM changes in numerous neurodegenerative disorders. For example, in a study of 
mild cognitive decline and Alzheimer’s, TBSS analysis revealed decreased anatomical 
connectivity (Damoiseaux et al. 2009), and a study in Parkinson’s connected the 
olfactory dysfunction present in the disease to WM changes (Ibarretxe-Bilbao et al. 
2010). In juvenile myoclonic epilepsy, TBSS revealed widespread WM abnormality 
(Focke et al. 2014) and demonstrated parallel changes in temporal lobe epilepsy 
(Focke et al. 2008). TBSS has also been used in a longitudinal settings, and an 
investigation of Huntington’s disease was able to demonstrate progressive decline 
in WM integrity over a course of 30 months (Poudel et al. 2015).  
The method was developed for analysing patient data, but with modifications the 
analysis can also be utilized in animal models. A study in a kainite model of epilepsy 
in rats revealed novel affected areas and confirmed tissue level changes associated with 
observed changes in diffusion (Sierra et al. 2011) and TBSS analysis of correlating 
changes in FA to the lack of myelin in a model of Pelizaeus-Merzbacher disease 
demonstrated the use of the method in mice (Ruest et al. 2011). TBSS has also 
been performed in non-human primates, and study in macaques was able to connect 
hippocampal WM-lesions to deficits in memory function (Meng et al. 2014). 
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1.3.4 X-ray computed tomography
Imaging techniques that provide sectional (tomographic) information through the 
use of penetrating waves (i.e. X-rays, gamma rays) are called tomographies, and the 
most commonly used method is x-ray computed tomography (CT). The method 
is extensively used in medical imaging, in addition to which it is widely utilized 
for example in security scanners, industrial radiography, archaeology and material 
physics. The explanation of its principles given here has been adapted from a book 
by Soimakallio et al. (Soimakallio et al. 2005). 
Different tissues, such as muscle, bone or fat have distinctive radiodensities, 
described by their Hounsfield unit values. When a x-ray beam is passed through a 
body or limb and detected at the other side, differences in the amount of absorbed 
x-rays by various tissues provide contrast and allows distinguishing between different 
structures. In CT, a series of two-dimensional x-ray images are acquired from different 
directions on a single axis of rotation, usually covering a 180-degree arc of the object 
of interest (Figure 6). Images from different angles are obtained either by moving 
the sensor around the target or by rotating the target. The back-projection principle 
is then utilised in calculating a three-dimensional presentation from the series of 
two-dimensional images. 
Figure 6.  Simplified principle of computed tomography. A series of two-dimensional x-ray 
images are acquired from different directions on a single axis of rotation, either by moving the 
sensor around the target or by rotating the target. The back-projection principle is subsequently 
utilised in calculating a three-dimensional presentation from the series of two-dimensional images. 
Picture by Joonas Saaranen
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While the need for ionizing radiation limits the usage of CT, it is still widely 
used in clinical settings and research. Whole body CT scans are performed for 
instance for trauma patients (Caputo et al. 2014) and brain CT is a common way 
of studying head trauma (Haydel et al. 2000). CT is also utilized in the study of 
bone structure, such as investigations of bone mineral density (BMD) (Schreiber, 
Anderson & Hsu 2014). X-ray tomography that reaches micrometre scale resolution 
is referred as microtomography (µCT) (Figure 7). Microtomography is also used in 
preclinical animal research, and has for instance been used as in the study of bone 
microstructure in a mouse model of thalassemia (Vogiatzi et al. 2010) and in the 
investigation of changes in bone mass and composition in a mouse model of obesity 
(Zhang et al. 2015). 
Figure 7. Computed tomography image of a mouse skull. A cross-sectional cut of a µCT-
image of a mouse skull shows the conch-shaped inner ear in the middle of the image, and the 
detail in the fine structure of the trabecular bone demonstrates the resolution obtained with 
microtomography system. The voxel size in this reconstruction is 10x10x10 µm.
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1.3.5 Transmission electron microscopy
The magnification achieved with conventional light microscopy is limited by the 
wavelength of photons in visible light and the resolution is not sufficient for viewing 
many subcellular structures. In these cases electron microscopes are used. Electron 
microscopes use accelerated electron beams for detection instead of visible light, and 
as electrons have much lower wavelength than visible light, electron transmission 
based detection can be utilized in visualizing much smaller structures, up to a 
resolution enabling the viewing of atoms (Pennycook 2012). The following simplified 
explanation of transmission electron microscopy (TEM) has been adapted from 
Williams and Carter (Williams, Carter 2009).
In transmission electron microscopy, a condensed electron beam, usually generated 
with a tungsten filament, is directed at a sample under vacuum. Samples are ultra thin 
sections of material or tissue, prepared using a microtome. In light microscopy, the 
visibility of certain structures is enhanced using stains that absorb light, and create 
contrast to the image. For TEM, compounds of heavy metals such as osmium, lead 
or uranium are used for staining. In bright field TEM, as the beam passes through 
the sample, the stain absorbs or diffracts electrons and thus highlights certain cellular 
regions or structures of interest. After passing through the sample, the electron beam 
is magnified and focused to form a coherent image, then captured with an imaging 
device, such as camera. Different systems of contrast formation are used, depending 
on the desired magnification and the studied sample. Due to the high magnifications 
obtained with TEM, the method is used for instance in nanotechnology for analysing 
particle size and geometry (Korbekandi et al. 2015), in virology for the investigation 
of infective properties of a hepatitis virus (Liu et al. 2014) and in histopathology for 
the investigation of cellular scale structures (Kuronen et al. 2012). 
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2 AIMS OF THE STUDY
The overall aim of this study was to elucidate the events contributing to the 
progression of progressive myoclonus epilepsy, EPM1, in an experimental mouse 
model, the Cstb–/– mouse. 
The specific aims of the study were:
Aim 1. To gain a comprehensive picture of EPM1 disease progression by conducting 
longitudinal MRI and DTI follow-up studies in Cstb-/- mice from pre-symptomatic 
to fully symptomatic stage (1-6 months). 
Aim 2. To investigate white matter (WM) changes in adult (6-month-old) Cstb-/- 
mice and evaluate the congruence of the findings in adult EPM1 patients. 
Aim 3. To evaluate the contribution of defective cystatin B function on bone 
pathology, metabolism and properties of osteoclasts in the Cstb-/- mouse using 
microtomography, bone histology and bone marrow derived osteoclast cultures.
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3 MATERIALS AND METHODS
3.1 CSTB–/– MOUSE (I,II,III)
Cystatin B-deficient mice (Cstb–/–) (Pennacchio et al. 1998) were used as an animal 
model of EPM1 in this study. The mice were obtained from the Jackson Laboratory 
(129-Cstbtm1Rm/J; stock #003486) and age- and gender matched 129SvJ wild-type 
mice served as controls. Animal experiments were approved by State Provincial 
Office of Southern Finland (ESLH-2007-05788/Ym-23: ESAVI-2010-07744/
Ym-23/ ESAVI-7039/04.10.03/2013). 
3.2 MAGNETIC RESONANCE IMAGING (I,II)
3.2.1 MRI volumetry (I)
In vivo MRI volumetry was performed on four Cstb-/- and four control female mice. 
Volumetry data were acquired at the age of 1, 2, 4 and 6 months. Animals were 
imaged under isoflurane anaesthetisia (1% isoflurane in 70% N2O / 30% O2,) and 
the body temperature was maintained at 37°C throughout imaging. A 4.7 T Varian 
UNITY INOVA MRI system and an actively-decoupled volume coil-quadrature 
surface coil set (Rapid Biomedical GmbH, Rimpar, Germany) was used for image 
acquisition. An adiabatic multi-slice spin echo sequence was used for acquiring 
anatomical images for volumetric analysis (Figure 8) (17 slices, 100 x 100 µm in-
plane resolution; matrix 256x256, slice thickness 0.75 mm, TE 20, 40 and 60 ms, 
TR 1.8 s, echo train length (NT) 4).  A mean image was averaged out of 3 TEs. 
ROIs were drawn on blinded data sets according to the mouse brain atlas (Franklin, 
Paxinos 1997) using in-house-buildt software Aedes 1.0. (Niskanen )(Figure 8). 
ROIs were drawn for the whole brain (excluding medulla), cerebellum, cerebral 
cortices, striatum and hippocampus for each time point. Statistical comparison 
was done using one-way analysis of variance (ANOVA) with Bonferroni post hoc 
correction. 
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Figure 8. ROI selection in in vivo volumetry. The image shows the ROIs for whole brain 
volume (red), striatum (purple), cortices (pink), hippocampus (yellow) and cerebellum (green) 
overlaid on the MR image stack of a 6-month-old control mouse brain.
3.2.3 Ex vivo diffusion tensor imaging (I,II)
3.2.3.1 Sample preparation (I,II)
For ex vivo brain DTI, we used 2-months-old (9 Cstb-/-; 6 female, 7 controls; 4 
female), 4-months-old (9 Cstb-/-; 5 female, 6 controls; 2 female) and 6-months-
old (9 Cstb-/-; 8 female, 4 controls; all female) mice.  Animals were anaesthetized 
with pentobarbital (Mebunat, 80-150 mg/kg ip, Orion, Finland) and intracardially 
perfused with PBS and sodium heparin (0.16ug/ml, Sigma), and then perfusion fixed 
with 4% paraformaldehyde (PFA) (4% by volume, Sigma) in phosphate buffered 
saline (PBS). The brains were then removed, and postfixed for 24h. The brains 
were then immersed in perfluoropolyether (Fomblin® LC08, Solway Solexis,) for 
ex vivo DTI. 
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3.2.3.2 Ex vivo DTI (I,II)
Imaging of the brains was performed with a 9.4 T vertical magnet (Oxford 
Instruments, Abingdon, UK) using a Varian DirectDrive console (Varian Inc. Palo 
Alto, USA). Data were acquired using a 3D fast spin echo sequence (echo time 
(TE) 28 ms, repetition time (TR) 1000 ms, matrix 128×64×64, zero padded to 
256×128×128, field of view (FOV) 20×10×10 mm³, echo train length = 2) and 
six individual 3D data sets with diffusion weighting in six orthogonal directions 
(diffusion time 17 ms, b-value 1000 s/ mm2). One reference data set without diffusion 
weighting was also obtained. Acquisition of one dataset took 16 hours.
3.2.3.3 Track based spatial statistics (I,II)
The TBSS analysis was performed as described in the original publications (Smith 
et al. 2006, Smith et al. 2007) with the modifications for use in rodents (Sierra et al. 
2011). First, the acquired DTI data were corrected for eddy current distortions using 
affine (linear) alignment with FMRIB’s Linear Image Registration Tool (FLIRT) 
( Jenkinson et al. 2002, Jenkinson, Smith 2001). The diffusion tensor model was 
calculated using a DTIFIT (Smith et al. 2004) program and resulting individual 
FA maps underwent the TBSS analysis. 
When we studied the development of WM-changes (I), the analysis of the data 
was performed with hemisphere-mirroring. The aim of hemisphere mirroring, as 
previously stated (Sierra et al. 2011) was to gain a larger sample from the same dataset. 
This is accomplished by treating different hemispheres of the brain of the same animal 
as repeated measurements thus acquiring a statistically more powerful sample, with a 
cost of losing the information about the laterality of the changes. The TBSS analysis 
comparing Cstb-/- mice with controls was performed at three time points (2, 4 and 6 
months). Additionally, changes in FA-values over time were investigated by analysing 
FA-changes from 2 to 6 months inside both Cstb-/- and control groups. In order to 
present all TBSS results in a common 3D space, thus making comparison of affected 
WM-tracts easier, all 44 animals (I) were also registered into a common template 
brain chosen as the best registration target. The EPM1 patient data included in the 
translational study (II) were analysed for the laterality of the WM changes. Because 
of this, the data from the 6-month timepoint were treated identically to patient data 
and re-analysed without hemisphere mirroring.
In brief, the following TBSS protocol was used to analyse the FA-maps. First, 
we applied free-search of the best registration target brain from the whole data 
set, in order to minimize the image warping required during co-registration. The 
calculated best target was used in subsequent TBSS scripts as a template into which 
final transformations were targeted to. All brains were then co-registered to the 
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template brain with affine and non-linear transformations, and a mean FA-image 
was calculated out of all brains in the analysis. A mean FA-image was then thinned 
into an FA-skeleton, by thresholding the image to an FA-value 0.2, and the same 
step was performed to each individual FA-map. Each FA-skeleton was then projected 
on the mean FA-skeleton and then co-aligned with the mean FA-skeleton. AD, 
RD and MD parameters were also brought to the same TBSS-skeleton space 
using the co-registration warp-fields and tract projection information obtained 
in FA processing. The spatially aligned diffusion parameter data were then fed to 
voxelwise cross-subject statistical analysis.  For all tensor parameters, null distribution 
in statistical testing was built up over 5000 permutations and a threshold free cluster 
enhancement (TFCE) method (Smith, Nichols 2009) was used to report significant 
findings (TFCE, p<0.05). In order to account for the repeated measurements in 
the hemisphere-mirrored data, an exchangeability block design was included in the 
random permutation testing. 
Quantitative FA-values were extracted from FA-skeletons (Figure 9) on regions 
of interest drawn manually (aided by the significant TBSS results) along the TBSS-
skeleton using a mouse brain atlas (Franklin, Paxinos 1997). Non-midline ROIs were 
first drawn on the left hemisphere and mirrored to the right side and corrected if 
there was asymmetry regarding the exact positioning of a tract in question. 
Figure 9. Co-aligning white matter tracts using a mean FA-skeleton. The mean FA-
skeleton, thresholded from co-aligned FA-maps to an FA value 0.2, is shown here in green 
overlaied on top of the mean FA-map, calculated as mean out of all co-aligned FA-maps in the 
group. 
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3.3 WHITE MATTER HISTOPATHOLOGY (II)
3.3.1 Cerebellar myelin staining (II)
Immunohistochemical staining was performed on paraffin embedded brain slices 
from 6-month-old animals. The animals were anaesthetized with pentobarbital 
(Mebunat, 80-150 mg/kg ip, Orion, Finland) and perfused intracardially first with 
PBS with 0.16 mg/ml heparin (Sigma, St. Louis, Missouri, USA) and subsequently 
with pH 7.4 4% PFA. Dissected brains were immersion fixed with 4% PFA, 
embedded in paraffin for sectioning and cut into 5 µm sagittal sections. 
The protocol for myelin basic protein (MBP) staining included quenching 
endogenous peroxidase activity (5% H2O2 in H2O), blocking with bovine serum 
albumin (5% in BSA, Sigma, St. Louis, Missouri, USA) in PBS. The primary 
antibody was incubated overnight at +4˚C (rat anti-MBP, 1:200, Chemicon, Billerica, 
Massachusetts, USA). For two animals (Cstb-/- n=2, both male; Control n=2, both 
male), immunoreactivity was detected use of biotinylated secondary antiserum IgG 
(1:1000; Vector Laboratories, Burlingame, California, USA) and a avidin-biotinylated 
peroxidase-Complex (Vectastain® Elite® ABC KIT, Vector Laboratories, Burlingame, 
California, USA) through reaction of diaminobenzidine tetrahydrochloride 
chromogen (DAB; Sigma, St. Louis, Missouri, USA). A background stain of Meyer’s 
hematoxylin (1:2 in H2O) was also used. For six animals (Cstb -/- n=3, control n=3, 
all female) immunoreactivity was detected through immunofluorecence using Alexa 
anti-rat secondary antibody (1:200, Invitrogen, Waltham, Massachusetts, USA). 
Slides were imaged using a Zeiss Axiovert 200 imaging microscope coupled with 
an AxioCam HRc camera and AxioVision Release 3.1 software (Carl Zeiss, Jena, 
Germany).  
3.3.1.1 Quantification of myelin basic protein immunoreactivity (II)
Cerebellar myelin basic protein staining immunoreactivity was quantified from 
immunofluorescence pictures using ImageJ 1.42 (Schneider, Rasband & Eliceiri 
2012). The background was subtracted with a built-in filter (Figure 10). The resulting 
image was subsequently thresholded into a binary image using a built-in movement 
algorithm. After this, round ROIs were placed on areas of white matter in the 
cerebellum by an observer blinded to the genotype of the animals (Figure 10). 
Areas of positive MBP stain were quantified as percentage of pixels over the binary 
threshold for positive MBP-stain. 
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Figure 10. Quantification of cerebellar MBP-staining. The left image shows image of green 
MBP immunofluorescence staining of cerebellar WM after the background subtraction. The 
right image shows the same image as binary after thresholding, with ROIs for quantification 
placed on the image. The positive MBP stain was measured as a percentage of pixels (black 
pixels) over the binary threshold for each ROI, and a mean percentage was calculated for each 
image. 
3.3.2 Transmission electron microscopy (II)
3.3.2.1 Sample preparation (II)
The samples for TEM were prepared from 6-month-old animals (Cstb-/- n=5, 2 
male, Controls n=4, 1 male). The animals were anaesthetized with pentobarbital 
(Mebunat, 80-150 mg/kg ip, Orion, Finland) and intracardially perfused using PBS 
with 0.16 mg/ml heparin (Sigma, St. Louis, Missouri, USA) and perfusion fixed 
with 3% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. Samples from WM in 
the cerebellum were obtained and immersion fixed with 3% glutaraldehyde for 24h 
and embedded in epoxy resin.
3.3.2.2 Aquiring electronmicrographs (II)
Toludine-blue stain (1% by weight solution, Sigma, St. Louis, Missouri, USA) 
was used for assessing the quality of the samples, and for selecting WM regions of 
interest for sectioning. The blocks were subsequently sliced using an ultra microtome 
and stained with lead citrate and uranyl acetate. Imaging was performed using 
JEOL 1400 TEM ( JEOL, Tokyo, Japan). From each animal, we acquired five fields 
with 12000x magnification (16.2 µm x 11.5 µm) of cross-sectional cerebellar WM 
(Figure 11).  
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Figure 11.  Transmission electron micrograph of a cerebellar white matter of a Cstb-/- 
mouse. In transmission electron microscope images, myelin sheaths of the axons can be seen 
as dark rings of electrondense material around the lumen of an axon. For quantification, we 
obtained images of cross-sectional WM with 12000x magnification.
3.3.2.3 Quantification of electronmicrographs (II)
From the electronmicrographs, we quantified axonal density and g-ratios (an 
index indicating the functional and structural integrity of the axon). G-ratios were 
quantified from ten randomly selected axons in each field (50 axons per animal) 
and calculated as a ratio of cross-sectional axon diameter to fibre diameter.  Axonal 
density was quantified by counting the number of axons in the electromicrographs 
(5 electronmicrographs per animal) . The number of axons showing degenerative 
changes, including the presence of vacuolar bodies or electrondense appearance, 
as well as the number of degenerated axons, was calculated. Quantification was 
performed with ImageJ 1.42. (Schneider, Rasband & Eliceiri 2012) by a blinded 
observer. 
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3.4 BONE MICROTOMOGRAPHY (III)
3.4.1 Sample preparation (III)
For microtomography, we used 3-month-old animals (Cstb-/- n=5, all male, Controls 
n=4, all male). The animals were anaesthetized with pentobarbital (Mebunat, 80-
150 mg/kg ip, Orion, Finland), intracardially perfused with phosphate buffered 
saline (PBS) with 0.16 mg/ml heparin (Sigma), then perfusion fixed with 4% 
paraformaldehyde. Hindlimbs were dissected, and post fixed for 24 h, then stored 
immersed in 70% EtOH.
3.4.2 Microtomography (III)
Ex vivo µCT data were acquired from the right hindlimb. During the imaging, the 
limbs were inserted into an in-house manufactured sealed tubular plastic imaging 
holder. A SkyScan 1070 µm CT scanner (SkyScan, Kontich, Belgium) was used, 
and the datasets were scanned with the following parameters: voxel resolution 20 
µm; X-ray tube potential 70 kVp; current 200 µA; and integration time 3900 ms. 
The object was rotated in 0.45° steps (total 182.45°). 
3.4.3 Bone morphology analysis from micrographs (III)
Cross-sectional image reconstruction was done using Nrecon 1.4 (SkyScan, Kontich, 
Belgium) (misalignment < 3, ring artefact reduction 11, beam hardening correction 
95%, intensity gap 0.005–0.150) and analysis and modelling were performed with 
CTan 1.4.4 (SkyScan, Kontich, Belgium) (Figure 12). Cross-sectional images 
were binarized using an attenuation coefficient range of 0.005 to 0.150. For the 
trabecular bone, volumes of interest (VOI) excluding cortical bone were defined at 
the metaphysis of the tibia, starting 20 slices (400 µm) below the lowest identified 
point of the growth plate and covering 50 layers (1000 µm) downward. Analysis 
of cortical bone analysis was performed from the diaphysis of the tibia. VOI was 
defined starting 4000 µm above the growth plate, covering 100 layers (2000 µm) 
upward. After this, low and high threshold values for bone intensity were set to 35 
and 250 respectively and the images analysed for 3D and 2D structural parameters 
as well as for BMD. 
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Figure 12. Computed tomography image of a control mouse femur. The high level of 
detail obtained by a modern computed tomography system enabled the study of porous tra-
becular bone structures in the mouse femur.
3.5 BONE HISTOLOGY (III)
3.5.1 Sample preparation (III)
For bone histology we prepared samples from the hindlimbs of Cstb-/- and control 
mice, age 1 month (Cstb-/-, n=13; controls, n=13) and 4 months (Cstb-/-, n=13; 
controls, n=13). The animals were anaesthetized with pentobarbital (Mebunat, 
80-150 mg/kg ip, Orion, Finland), intracardially perfused with phosphate buffered 
saline (PBS) with 0.16 mg/ml heparin (Sigma, St. Louis, Missouri, USA), then 
perfusion fixed with 4% paraformaldehyde. Hindlimbs were dissected and post fixed 
for 24 h, then stored immersed in 70% EtOH. Histology samples were prepared from 
distal femurs and proximal tibias. Prior to cutting, the bones were decalcified in 5% 
formic acid, embedded in paraffin and cut into 5 µm-thick sections for mounting 
on microscopy slides. Femur length was measured using a micrometer  (Cstb-/-, n=5; 
controls, n=3) (Figure 13).
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Figure 13. Measurement of femur length. Femur length was measured from the fixed right 
femur of each mouse using a micrometer.
3.5.2 Histological quantification of bone morphology (III)
Histological quantification of bone morphology was performed from hindlimb 
samples from 1- and 4-month-old animals (Cstb-/-, n=8; controls, n=8). The cross-
section of the functional zones in the growth plate (the resting-, proliferative- and 
hypertrophic zones) was measured as previously described (Nurmio et al. 2011). 
Briefly, the bone sections were stained with hematoxylin-eosin and the thickness 
of the zones was quantified using a Leica QWin Pro analysis system (Leica 
Microsystems GmbH, Wetzlar, Germany). The mature multinucleated osteoclasts 
were counted as previously described (Laitala-Leinonen et al. 2006) from samples 
stained with the leukocyte acid phosphatase kit (TRAP-kit) (Sigma Aldrich, St. 
Louis, Missouri, USA). 
3.5.3 Immunohistological quantification of osteoclast morphology (III)
Immunohistological stainings for osteoclast cat K and tartrate-resistant acid 
phosphatase 5b (TRACP 5b) were quantified as described previously (Nurmio et 
al. 2011). In brief, stainings were done using Cat K monoclonal antibody in 1:600 
dilution (Acris Antibodies GmbH, Hiddenhausen, Germany) and TRACP 5b 
polyconal antibody (1:500 , in-house manufacture (Halleen et al. 1998)). The number 
of immunopositive cells and the intensity of the staining were quantified using 
Leica QWin Pro analysis system (Leica Microsystems GmbH, Wetzlar, Germany). 
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3.6 ONE MARROW DERIVED OSTEOCLAST CULTURES (III, 
UNPUBLISHED)
Osteoclasts were cultured as described previously (Laitala-Leinonen et al. 2006). In 
brief, animals were euthanized with CO2 and decapitated. Both femurs and tibias 
were harvested for bone marrow, which was then homogenized to a single cell 
suspension. The cell suspension was then left to adhere on 60 mm plates for 4 h in 
37 oC. The non-adhered cells, which include the macrophage precursors, were washed 
and plated at 100 000 cells/well on 96-well plates in alpha modification of Eagle’s 
medium (a-MEM). To promote the differentiation of the haematopoietic precursors 
into macrophages, the culture media included macrophage colony stimulating factor 
(M-CSF) 20 ng/ml (RnD systems, Minneapolis, MN, USA). Every 48 hours half of 
the media was replaced, and after the first 48h of culture, 100 ng/ml receptor activator 
of nuclear factor kappa-B ligand (RANKL, Peprotech, Offenbach, Germany) was 
included to facilitate osteoclast differentiation.
3.6.1 Quantification of cultured osteoclasts (III)
Osteoclasts were cultured for 6 days with RANKL, after which they were fixed 
with 4% PFA. Mature osteoclasts were defined as multinuclear (three or more 
nuclei) tartrate resistant acid phosphatase positive cells and for identifying the 
osteoclasts we stained the cultures using a leukocyte acid phosphatase kit (TRAP-
kit, Sigma Aldrich, St. Louis, Missouri, USA). The nuclei were counterstained with 
Hoecst (1:500, Sigma Aldrich, St. Louis, Missouri, USA). Each well of the cultures 
was subsequently imaged using an Olympus ScanR system (Olympus GmbH, 
Hamburg, Germany), which is a modular epifluorescence microscope designed for 
fully automated image acquisition and analysis. The number of mature osteoclasts 
was counted from 22 culture wells for both genotypes (pooled from three mice 
per genotype in three independent experiments). The size of the osteoclasts was 
quantified from 9 wells for both genotypes (pooled from four mice per genotype). 
The number and the area of the cells was quantified by an observer blinded to the 
genotype of the cells using ImageJ version 1.48 (Schneider, Rasband & Eliceiri 
2012).
3.6.2 Cathepsin K assay (III)
The cat K enzymatic activity assay was performed with osteoclasts cultured for 5 days 
on RANKL, after which the activity of cat K was assessed using Magic Red Cat K 
assay Kit (Immunochemistry Technologies, Bloomington, MN, USA) according to 
the manufacturer’s instructions. Cat K present in the cultures cleaves a cresyl violet 
based red fluorochrome from a peptide, and the amount of produced fluorescence can 
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be then quantified with a plate reader.  We measured the fluorescence from 8 wells 
for both genotypes (cells pooled from 4 mice per genotype) using a Pherastar FS 
plate reader (BMG Labtech, Ortenberg, Germany). 
3.6.3 Osteoclast pit formation assay (III)
The resorptive capacity of osteoclasts was assayed using 96-well Corning osteo-
assay surface plates (Corning, New York, NY, USA). They are cell culture plates that 
contain a synthetic bone coating that is digested by mature osteoclasts. Culturing 
and analysis were performed according to the manufacturer’s recommendations, 
and 300000 cells/well were plated in a-MEM including M-CSF 20 ng/ml (RnD 
systems, Minneapolis, MN, USA) with half of the media replaced every 48 h. To 
facilitate differentiation of osteoclasts, after 48h 100 ng/ml RANKL was added 
(Peprotech, Offenbach, Germany). 
The cells were cultured for 7 days with RANKL, then fixed with 4% PFA and 
washed with PBS. Formed resorption pits were exposed for microscopy by removing 
the cells with a 5 min treatment of 10% sodium hypochlorite. The formed resorption 
pits in the synthetic bone coating were then visualized by counterstaining the wells 
coating with 1% toluidine blue (Sigma, St. Louis, Missouri, USA). This makes the 
resorption pits discernible as clear unstained regions in the blue stained coating. The 
wells (Cstb-/-, 10 wells; controls, 10 wells, cells pooled from 4 mice per genotype) were 
subsequently imaged with Olympus ScanR (Olympus GmbH, Hamburg, Germany) 
and a matrix of 6x8 images per well at 10x magnification was obtained. The number 
and the size of the pits were quantified with proprietary ScanR software version 
1.3.0.3. (Olympus, Hamburg, Germany) (Figure 14).  An edge-detection feature 
in the software was used for finding the edges of the resorption pits based on large 
image intensity difference between the dark synthetic bone and the light resorption 
pit. The detected pit edges were then filtered by object size for excluding false positive 
hits caused by well edges. Second filtering was done for a staining intensity threshold 
was used to exclude black staining artefacts left from the toluidine blue staining. 
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Figure 14. Number and size of formed resorption pits quantified using the ScanR 
software. Image shows a screen capture from program used in quantifying the resorption 
pit assay plates. The light resorption pits stand out on dark toluidine blue stained synthetic 
bone. The image shows the automated detection of resorption pit edges, with the positive hits 
highlighted with green squares, with almost all resorption pits detected. Black detritus seen in 
the image is staining artefact.
3.6.4 Fluorescence activated cell sorting (III)
The number of macrophage precursors in bone marrow was determined using 
fluorescence activated cell sorting (FACS). In brief, animals (3-month-old male 
mice, Cstb-/- n=5; control, n=3) were euthanized with CO2 and decapitated. Bone 
marrow was collected from both femurs and tibias by flushing with in a-MEM using 
a syringe and a G23 needle. The cell suspension was homogenized to a single cell 
suspension in a-MEM and 1000000 cells were counted for staining. Cells were first 
briefly treated with a blocker (CD16/CD32, eBioscience, San Diego, California. 
USA) and then incubated for 30 min with an antibody cocktail for lineage exclusion 
(CD3e, CD11b, CD45R (B220), Ly-6G and Ly-6C (Gr-1), TER-119 (Ly-76); 
BD Pharmingen, San Jose, California, USA). Cells were then washed with PBS and 
incubated for 30 min on ice with streptavidin conjugated FITC stain and antibodies 
for Sca-1 and cKit (BD Pharmingen, San Jose, California, USA). After a final wash 
with PBS, the cells were counted with the FACScalibur system (BD Biosciences, 
Franklin Lakes, New Jersey, USA). The data were analysed with Flowing Software 
software (Flowing Software 2.5.1) (BD Biosciences, Franklin Lakes, New Jersey, 
USA). 
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3.6.5 Cell viability assay (III)
Cell viability in osteoclasts was studied using CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (Promega, Fitchburg, Wisconsin, USA). Osteoclasts (Cstb-
/- mice n=3, all male; control mice, n=3, all male; cells pooled) were cultured for 48h, 
and the assay was performed according to manufacturer instructions. In brief, after 
administering 40 µl of the reagents to each well, the cells were incubated for 2h at 
37oC. The absorbance, indicating amount of viable cells, was measured  at 490 nm 
using a Wallac Victor2 plate reader (Perkin Elmer, Waltham, Massachusetts, USA). 
3.6.6 Osteoclastic apoptosis assay (III)
Osteoclast apoptosis was assessed using TACS Blue Label TUNEL-based Apoptosis 
Detection Assay (R&D Biosystems, Minneapolis, Minnesota, USA). Osteoclasts 
(Cstb-/- mice n=3; control mice, n=3, cells pooled) were cultured 6 days on RANKL, 
the cells were fixed with 4% PFA and then washed with PBS. One well of control 
cells were treated with DNA digesting enzyme included in the kit, forming a positive 
control for tunel staining. The apoptosis assay was then performed for the positive 
control, Cstb-/- and control cells according to manufacturer instructions. 
3.6.7 Quantitative real time PCR (III)
Osteoclasts (Cstb-/- mice n=3, all male; control mice, n=3, all male; cells pooled) 
cultured for 6 days on RANKL were analysed for gene expression changes. RNA 
was isolated with a Qiagen RNAeasy kit (Qiagen, Heiden, Germany) according to 
the manufacturer instructions. A Qiagen RT² Profiler PCR Array ostegenesis kit 
(Qiagen, Hilden, Germany) was then used to assess gene expression and Qiagen 
RT² Profiler data analysis web portal (Qiagen, Hilden, Germany) was used for 
determining differences in Cstb-/- osteoclast gene expression compared to that of 
controls.
3.7 OSTEOBLAST CULTURES (UNPUBLISHED)
Osteoblasts were cultured and characterized as described previously (Morko et al. 
2009). In brief, animals were euthanized with CO2 and decapitated. Both femurs and 
tibias were harvested for bone marrow, which was then homogenized to a single cell 
suspension. The cell suspension was then seeded into culture flasks in a density of 106/
cm2 and cultured for 7 days in a-MEM media with 10 mM Na-β-glycerophosphate 
and 50 µg/ml ascorbate-2-phosphate and with 10-8 M dexamethasone (Sigma, St. 
Louis, Missouri, USA). After 7 days of culture, the adherent cells were scraped, 
washed and plated at 10 000 cells/well onto 24 well plates. The cells were cultured for 
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another 14 days, without dexamethasone, and fixed with 4% PFA.  The osteoblasts 
were stained for morphological analysis with with leukocyte alkaline phosphatase 
kit according to manufacturer instructions (Sigma, St. Louis, Missouri, USA). For 
assessing osteoblast function, von Kossa staining was also performed with 2% sodium 
nitrate and 2.5% sodium thiosulfate solutions (Sigma, St. Louis, Missouri, USA).
3.8 STATISTICAL ANALYSIS (I, II, III, UNPUBLISHED)
The statistical analysis of data was done using one- and two-way analysis of variance 
(ANOVA), with Bonferroni correction used where applicable. The statistical 
analysis was performed with Microsoft Excel for Mac 2011 (Microsoft, Redmond, 
Washingon, USA) and GraphPad Prism 5.0c software (GraphPad Software, San 
Diego, California, USA), with P-values smaller than 0.05 considered significant. 
Statistical methods for the TBSS-analysis (I,II) have been detailed in their 
corresponding methods sections (3.2.2.3).
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4 RESULTS AND DISCUSSION
4.1 WHITE MATTER DEGENERATION AND ATROPHY IN 
CSTB-/- MICE (I,II, UNPUBLISHED)
4.1.1 Early and widespread atrophy in Cstb-/- mice (I)
Previous imaging studies have reported cerebellar, thalamic and cortical atrophy in 
EPM1 patients (Mascalchi et al. 2002, Koskenkorva et al. 2009). Correspondingly, 
the brain volume in adult patients has been shown to be decreased by 10% compared 
to healthy controls (Koskenkorva et al. 2009). The limited histopathological data 
on EPM1 patients has shown loss of cerebellar granule and Purkinje cells as well as 
neuronal degeneration and neuronal loss in the cerebral cortex, striatum, thalamus and 
brain stem (Cohen et al. 2011, Eldridge et al. 1983, Haltia, Kristensson & Sourander 
1969, Koskiniemi et al. 1974). Even though the progressive nature of atrophy 
in EPM1 has been difficult to demonstrate, the severity of myoclonus has been 
associated with cortical thinning (Koskenkorva et al. 2009). The histopathological 
findings in the Cstb-/- mice are very similar to those in EPM1 patients, although 
atrophy is more severe in the Cstb-/- mouse brain (Shannon et al. 2002, Tegelberg 
et al. 2012). In order to elucidate the progress and the spatiotemporal dynamics of 
the atrophy, a longitudinal in vivo MRI volumetry study in Cstb-/- mice was carried 
out. The time points for the study were selected to correspond with our previous 
histology study (Tegelberg et al. 2012) and the manifestation of disease symptoms 
in the mouse model: the first signs of myoclonus manifest at 1 month of age, and 
by 6 months of age the animals develop ataxia and become fully symptomatic 
(Pennacchio et al. 1998). 
The MRI volumetry revealed the whole brain volume, excluding the medulla, to 
be significantly reduced in Cstb-/- mice compared to controls already at 1 month (I, 
Figure 1 A). Whereas the whole brain volume in controls increased until 4 months, 
in Cstb-/- mice the atrophy overtook the growth and the brain volume decreased 
from 2 months onwards (I, Figure 1 A), highlighting the severity of the atrophy 
and suggesting that the brain size never reaches that of the controls. No difference 
in cerebellar volume between controls and Cstb-/- mice was observed at 1 month, but 
from at 2 months onwards, the cerebelli of Cstb-/- mice were significantly smaller (I, 
Figure 1 B). In control mice the cerebellum continued to grow in size until 2-month 
timepoint, whereas in Cstb-/- mice, the cerebellar volume progressively decreased from 
1 month onwards (I, Figure 1 B). Progression of the volume loss in the cerebral cortex 
(I, Figure 1 C) was similar, with Cstb-/- mice showing a significant decrease from 2 
months onwards. On the contrary, the striatum and the hippocampus (I, Figure 1 
D and E) showed significant reduction in volume only at 6 months of age. 
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The data show that the atrophy has an early onset and is progressive. The difference 
in volume between the groups was accentuated over the observation period as the 
volume in the control group continued to grow whilst the brain volume decreased 
in the Cstb-/- group, emphasising the progressive nature of the atrophy. Furthermore, 
the heterogeneity in the degree and rate of volume loss in different brain regions 
would indicate that some cell populations are more sensitive to the lack of CSTB 
than others. Still, even though we did not detect statistically significant atrophy of 
individual brain regions at the 1-month time point, the cumulative volume loss from 
individual regions added up to a significantly decreased whole brain volume at this 
point. As Cstb-/- mice show signs of neuroinflammation and microglial activation 
already at age of p14 (Okuneva et al. 2015, Tegelberg et al. 2012) and neuronloss at 1 
month (Tegelberg et al. 2012), the severe and early atrophy shown here emphasises the 
presence of early changes in EPM1, and suggest that that disturbed developmental 
processes constitute to the observed changes. 
4.1.2 Widespread and progressive FA decrease in the Cstb-/- mice (I)
In agreement with the findings of progressive atrophy demonstrated by the results, 
loss of neuronal volume in the posterior fossa in EPM1 patients has been reported 
(Mascalchi et al. 2002) and a recent VBM study showed GM volume loss in bilateral 
cortical motor areas and thalami (Koskenkorva et al. 2009). The atrophy in the 
motor cortex matched the results of a navigated transcranial magnetic stimulation 
(TMS) study, which could be indicated in cortical inhibitory networks (Danner 
et al. 2009). Myoclonus, the pathophysiological basis of which is currently not yet 
well understood, is the most disabling symptom in EPM1 and therefore it can be 
assumed that motor pathways are widely affected. The findings from our previous 
histology study (Tegelberg et al. 2012) as well the drastic and early cortical atrophy 
(I) support this hypothesis, even though a previous histology study showed no 
indication of myelin changes beyond WM gliosis (Shannon et al. 2002). The presence 
WM changes in Cstb-/- mice were investigated using DTI and the obtained data 
analysed with TBSS. No previous MRI data from the mouse model existed, and 
histopathological data from Cstb-/- mice were scarce, making a hypothesis-based 
ROI selection with manual quantification of DTI data an unfeasible approach. Also, 
the previously described (4.1.1) prominent atrophy could hinder the ROI selection 
and further encouraged the use of an automated approach. The study period for the 
experiment was selected to complement the in vivo volumetry (4.1.1) with 2, 4 and 
6 months time points analysed. 
Ex vivo FA TBSS analysis of the DTI data revealed significant decrease in 
FA compared to the controls already at the 2 months timepoint (I, Figure 2 A; 
blue colour). The FA decrease was observed on several brain regions, including the 
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cerebellum, cerebral cortex, external/internal capsule, hippocampus, hypothalamus, 
and thalamus, with the most severe changes in the cerebellum and the thalamus (I, 
Table 1). These results highlight the drastic nature of the cerebellar and thalamic 
changes and early onset of WM changes, as indicated by FA decrease. By 4 months 
of age, more widespread areas of decreased FA within the cerebellum, cerebral 
cortex, external/internal capsule, hippocampus, hypothalamus, and the thalamus 
were observed  (I, Figure 2 A; yellow colour). Furthermore, many brain regions not 
shown affected by the TBSS at 2 months, including the corpus callosum, medulla, 
and the striatum, were showing significant decrease in FA by 4 months (I, Figure 
2 A; yellow colour). The new affected areas that emerge over time emphasise the 
progressive nature the changes. At 6 months, the decrease in FA was seen extending 
on larger areas on the previously affected brain regions and spreading most notably 
in the cerebellum, corpus callosum, hypothalamus and thalamus (I, Figure 2 A; red 
colour). Contrary to other regions, at 6 months of age, only minor changes were 
observed in the hippocampus. The TBSS analysis also showed significantly higher 
RD in the thalamus and the cerebellum of the Cstb-/- group at 4 months and in the 
cerebellum at 6 months (Unpublished, Figure 15; I, Table 1). As no changes in 
AD or MD were observed, it is likely that increase in RD contributes the most to 
the observed decrease in FA, at least at the timepoints of 4 and 6 months. Like the 
observed atrophic changes, the FA decrease was progressive and spatiotemporally 
heterogeneous. Based on these findings, the sequence of the pathological events in 
the Cstb-/- mice has been detailed in Figure 3 (I, Figure 3). The order and timing of 
the observed changes indicate that the early-onset non-uniform microglial activation, 
astroglial activation, neuron loss, myoclonus (Pennacchio et al. 1998, Tegelberg et 
al. 2012) and the atrophy shown in 4.1.1 precedes the observed the FA decrease. 
Thus the cascade of previous neurodegenerative events would indicate that the WM 
changes suggested by the FA decrease are most likely a secondary phenomenon to the 
preceding pathological changes and not as such directly caused by the lack of CSTB. 
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Figure 15. Areas of increased RD in 4- and 6-month-old Cstb-/- mice. Areas of significantly 
increased RD (TFCE p<0.05, corrected for multiple comparisons) in 6-month-old Cstb-/- mice 
(red) and in 4-month-old Cstb-/- mice (yellow) overlaid on a mean FA image of the study 
population. Both exhibit changes in the cerebellum, with significant changes seen on also other 
areas, including the thalamus, in the 4-month-old group. This is likely due to the larger amount 
of analysed brains in the 4 month group. No areas of decreased RD were observed.
4.1.3 On-going pathological processes hinder WM maturation in 
the Cstb-/- mice (I)
A longitudinal TBSS analysis was also performed for Cstb-/- and control groups, 
comparing the changes in FA from 2 to 6 months in each group. The results of this 
analysis showed that FA in the WM changed as the animals aged and the WM 
matured (I, Figure 2 B; I, Table 1). TBSS analysis in the control group revealed 
that the FA-values in most WM tracts at 2 months were significantly lower when 
compared to values at 6 months (I, Figure 2 B, pink colour), demonstrating FA 
increase in the WM as the animals age. In line with the results, previous studies 
have reported FA increase over time in healthy mice, and this is thought to reflect 
the maturation of the WM as the reorganization and compaction leads to increased 
fibre tract coherence (Larvaron et al. 2007, Chahboune et al. 2007). In concordance 
with our findings, these processes have been demonstrated to continue well beyond 
2 months of age (Verma et al. 2005). Similar FA increase was also observed in the 
Cstb-/- group (I, Figure 2 B, green colour), although the FA increase was detected 
in fewer brain regions. Also, on some brain regions such as the hypothalamus, 
thalamus and cerebellum, the changes were detected only in restricted sub-regions. 
The less pronounced FA increase over time therefore is likely to reflect the underlying 
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degenerative changes that hinder the WM maturation. 
We had previously performed TBSS analysis of DTI data in another mouse 
model of a neurodegenerative disease, ceroid lipofuscinosis type 8 (CLN8). While 
the animals displayed WM-changes in form of delayed myelination (Kuronen et al. 
2012), TBSS was not able to discern this defect (unpublished results), demonstrating 
that even drastic WM changes that do not cause changes in FA remain undetected 
with TBSS. However, in addition to a previously reported investigation on the WM 
changes in the mouse model of the Pelizaeus-Merzbacher disease114, the studies 
reported in this thesis (I, II) are among the first demonstrating the use of TBSS 
in investigating neurodegenerative changes in mice. Furthermore, longitudinal 
TBSS-studies have previously only been performed in patients (Poudel et al. 2015, 
Madhyastha et al. 2014), and these results introduce the use of TBSS in the study 
of progressive WM changes in animal models of neurodegeneration. The findings 
also show the feasibility of longitudinal TBSS as a tool for following FA changes 
related to normal WM maturation and reorganisation. 
4.1.4 Axonal degeneration in Cstb-/- mice (II)
Since the decreased FA (I) suggested progressive WM changes in the brain of the 
Cstb-/- mice, immunohistochemical analysis was performed in order to link DTI 
findings to tissue level changes. The longitudinal FA TBSS (I, Figure 2 A; Table 
1) indicated the cerebellum as the most severely affected brain region with early 
onset of damage. Combined with the previous histological data available from the 
region (Tegelberg et al. 2012, Shannon et al. 2002), the histological investigation 
of WM changes was conducted from of 6 month old Cstb-/- mice, with quantitative 
analysis performed on the cerebellum. 
The immunohistochemical staining of MBP showed decreased immunoreactivity 
in the brain of Cstb-/- mice, most notably in the cerebellum (II, Figure 2 A, B) and 
quantification of the  immunoreactivity revealed significant (p=0.027) decrease in 
MBP staining intensity in the Cstb-/- mice. Immunohistochemistry results indicated 
demyelination as the most likely cause of the FA decrease. Thus myelination was 
studied by using TEM images for determining axonal g-ratios, an established 
index describing axonal myelination (Chomiak, Hu 2009). As the quantification 
of g-ratios from TEM images did not indicate any difference in axon myelination 
between Cstb-/- mice and controls (g-ratios: Cstb-/- 0.71±0.01 vs. Control 0.69±0.02), 
it seemed unlikely that the changes in axon myelination cause the observed FA 
decrease. Therefore changes in axonal density were studied as a possible source for 
decreased MBP-immunoreactivity. This revealed a tendency toward lower axonal 
number in the Cstb-/- animals (Cstb-/- 38±7 vs. control 56±9 per field; p=0.065). As 
the electromicrographs of Cstb-/- mice exhibited an unusual amount of dead and 
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degenerating axons, we continued to investigate axonal degeneration. This revealed 
significantly more dead and degenerating axons (Cstb-/- 2.09±0.29 vs. control 
0.48±0.19 per field, p=0.002) in the cerebellar WM of the Cstb-/- animals. The high 
number of degenerating axons, combined with the lower axonal density indicated a 
drastically higher amount of axon damage in Cstb-/- mice compared to the controls. 
Cstb-/- animals had one axon showing degenerative changes in one for every 19 healthy 
axons, whereas controls had the ratio of one in 117 (II,Figure 3 A,- C). 
In light of these results, it appears that the axonal degeneration with consequent 
loss of whole fibres leads to a higher extracellular volume in the WM. As increased 
axonal spacing subsequent to axon loss has previously been associated with an increase 
in RD (Sen, Basser 2005), it is likely that the larger extracellular volume subsequently 
leads to an increase in RD, corresponding with the changes observed in the cerebellum 
at 4 and 6 months (Unpublished, Figure 15), the most severely affected brain region. 
The increase in RD in turn translates into decrease in FA. Therefore it is likely that 
the WM tracts exhibiting decreased FA are undergoing local axon loss matching the 
one demonstrated in the cerebellum of the Cstb-/- mice. The results also highlight FA 
as a more robust indicator of WM damage, since FA TBSS is able to show significant 
changes on most major WM tracts compared to the limited changes illustrated by 
the RD TBSS. 
4.1.5 White matter degeneration in EPM1 is caused by axon loss (II, 
Unpublished)
The correspondence of WM changes present in EPM1 patients and Cstb-/- mice was 
investigated in a translational setting. A TBSS-analysis of the DTI data comparing 
adult EPM1 patients and healthy controls (II) was performed without hemisphere 
mirroring, since this facilitated the study of the laterality of the changes between 
the hemispheres. The approach was matched in the animal model by comparing 
the DTI data from the fully symptomatic 6-month-old Cstb-/- mice with controls 
in a new analysis without the hemisphere mirroring. The TBSS analysis of DTI 
data revealed the WM of EPM1 patients to be widely affected. The degree and the 
widespread nature of the damage was highlighted by the global FA decrease along 
the TBSS skeleton (II). The Cstb-/- mice revealed corresponding changes with a 
significantly decreased global FA over the TBSS skeleton (Cstb-/- 0.397± 0.0018 
vs. control 0.415 ± 0.0057, Student’s t-test p=0.022). The TBSS-analysis showed 
significantly decreased FA on almost all major WM tracts of EPM1 patients, with 
parallel changes in more limited brain regions observed in the Cstb-/- mice (II, 
Figure 1 A, B; Table 3E).
TBSS revealed previously overlooked affected brain regions both in EPM1 patients 
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and Cstb-/- mice, the most notable of these being the changes in the cerebellum in 
patients and in the thalamus in Cstb-/- mice. Cerebellar changes in some autopsied 
EPM1 patients have been previously reported, but these have been attributed 
to phenytoin treatment (Eldridge et al. 1983).  While a recent histopathological 
study showed cerebellar changes in an EPM1 patient with no history of phenytoin 
treatment51, the discrepancy between extensive cerebellar changes in the Cstb-/- mice 
(Tegelberg et al. 2012, Pennacchio et al. 1998, Shannon et al. 2002) and the minor 
changes in patients have been attributed to differences in pathologies between the 
species. As DTI revealed cerebellar changes in both the EPM1 patients and the adult 
mouse model of the disease, our data suggest that cerebellar changes are a common 
characteristic of the disease. Due to the cerebellar role in movement coordination, 
it is also possible that these changes contribute to the ataxia present in the disease. 
Furthermore, a VBM study in EPM1 patients showed grey matter volume loss in 
the thalamus (Koskenkorva et al. 2009) and histological analysis has indicated the 
thalamus to be affected in EPM1 patients (Koskiniemi et al. 1974). Before a recent 
report by our group about microglial activation, followed by astrocytosis and neuron 
loss in the thalamocortical system of Cstb-/- mice (Tegelberg et al. 2012), there were no 
reports of the thalamus being affected in Cstb-/- mice. Taken together with the current 
data, the findings emphasize the involvement of the thalamus in the pathogenesis 
of EPM1 and the discovery of previously overlooked affected areas highlight the 
benefits of the use of the hypothesis free approach of TBSS.
In EPM1 patients, the majority of voxels with decreased FA corresponded to 
increased RD and MD while AD was unchanged (II). In patients and in mice, both 
hemispheres showed equivalent FA changes, indicating that WM damage displays 
no laterality. TBSS comparison between the Cstb-/- group and the controls did not 
show significant decrease in AD, MD or RD. However, the TBSS revealed the 
Cstb-/- group to have significant increase (TFCE p<0.05 with multiple comparison 
correction) in cerebellar RD (Unpublished, Figure 16). As a whole, increased RD 
(and to some degree, MD) would appear to be the main contributors to the FA 
decrease in EPM1 patients and Cstb-/- mice. The TEM results indicated that the 
underlying cause of these changes is axonal degeneration. Decreased FA together with 
increased RD and MD coinciding with axonal death has been reported in patients 
with amyotrophic lateral sclerosis (Cosottini et al. 2005), corpus callosotomy (Concha 
et al. 2006), and traumatic WM injury (Sidaros et al. 2008). The changes seen in the 
brains of EPM1 patients follow a pattern of chronic WM degeneration, reflecting 
both myelin and axonal loss (Concha et al. 2006, Sun et al. 2008, Burzynska et al. 
2010). Thus it is likely that the brain structures that display lowered FA in EPM1 
patients are undergoing a local pathology similar to that illustrated in Cstb-/- mice. The 
treatment resistant myoclonus has been previously considered predominantly cortical 
in nature (Kälviäinen et al. 2008, Koskenkorva et al. 2009). Altered inhibition in the 
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thalamocortical system of the patients has previously been demonstrated (Mervaala 
et al. 1984, Mervaala et al. 1986), and a thalamocortical dopaminergic defect has 
been reported (Korja et al. 2007b). The TBSS results indicate that in EPM1 there are 
widespread WM alterations including the subcortical WM, the pyramidal tracts and 
thalamus that parallel previously reported GM volume loss in the motor cortex and 
thalamus (Koskenkorva et al. 2009). Both the cerebellum and thalamus are linked to 
motor function (Manto et al. 2012, Sommer 2003), and the early manifestation of 
both the atrophy and WM changes at these regions combined with the coinciding 
emergence of myoclonus at one month of age emphasize thalamic and cerebellar 
involvement in the myoclonus.  Therefore it is likely that the motor disturbances 
in EPM1, myoclonus included, are not only cortical in nature but also involve the 
thalamocortical system and are augmented by the impaired inhibition and movement 
control by the damaged cerebellum. Furthermore, the novel information about the 
disease progress suggest that possible therapies in EPM1 should be targeted to the 
early stages of the disease, as the atrophy and WM damage are irreversible and are 
likely to contribute to the severe treatment resistant myoclonus in patients. 
Research of the mouse model of multiple sclerosis has shown microglial cathepsin 
K, which is inhibited by CSTB, to contribute to the WM damage present in the 
disease (Ma et al. 2007). Moreover, the mice deficient in CSTB and cathepsin B 
undergo less severe cerebellar atrophy and the cathepsin B levels are known to be 
increased in cells of both the EPM1 patients and the Cstb-/- mice (Houseweart et 
Figure 16. TBSS comparison of RD between 6-month-old Cstb-/- mice and controls 
without hemisphere mirroring shows increased RD in the cerebellum. Areas of 
significantly increased RD (TFCE p<0.05, corrected for multiple comparisons) are shown in red 
overlaid on a mean FA image of the study population, and show elevated RD in the cerebellum 
of Cstb-/- mice. The results show some laterality in the changes, and when compared with 
the changes with hemisphere mirroring, demonstrate that more significant changes can be 
observed due to the more robust statistical processing. No areas of decreased RD were observed.
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al. 2003, Lehtinen et al. 2009, Rinne et al. 2002). Findings in Alzheimer’s disease, 
Parkinson’s disease, amylotropic lateral sclerosis and Huntington’s disease also show 
activation of microglia and the secretion of pro-inflammatory cytokines to play a 
role in the pathogenesis (Prinz, Mildner 2011). Therefore, elevated cathepsin B levels 
combined with deficient inhibitive function of CSTB could contribute following 
WM loss. 
4.2 BONE PHENOTYPE IN CSTB–/– MICE (III)
4.2.1 CSTB deficiency affects bone structure and osteoclast 
homeostasis (III)
In addition to the widely documented neurological features, EPM1 patients 
exhibit heterogeneous bone changes, including diffuse thickening of cranial bones, 
arachnodactyly, scoliosis, enlarged paranasal sinuses, and accessory ossicles of the foot 
(Danner et al. 2013, Korja et al. 2007a, Suoranta et al. 2012). The cause and origin 
of these bone changes is currently unknown and the bone phenotype of Cstb-/- mice 
had not been characterised before. Therefore it was justified to investigate whether 
the bone phenotype is recapitulated in Cstb-/- mice and examine the function of 
CSTB in bone metabolism and especially osteoclasts using the Cstb-/- mouse model. 
The bone structure in hindlimbs of Cstb-/- mice was studied with µCT. The 
analysis of the cortical BMD did not show any change (Cstb-/- 0.208±0.01 vs. 
control 0.189±0.06), while the trabecular BMD was significantly higher in the Cstb-/-
mice (0.339±0.02 vs. controls 0.243±0.01, T-test p=0.001). Analysis of the three-
dimensional bone structure from the µCT data revealed changes in trabecular bone 
composition (III, Table 1), most importantly increased trabecular thickness and 
increased bone volume percent (bone volume / tissue volume). The diffuse thickening 
of the skull in EPM1 patients is known also to affect the trabecular bone (Suoranta 
et al. 2012, Korja et al. 2007a). While no data on BMD measurements from EPM1 
patients exist, the osteoporotic changes reported in trabecular bone (Suoranta et al. 
2012) could indicate decreased BMD. 
These findings indicate that the lack of CSTB in the mouse model leads to altered 
formation of bone tissue especially in the trabecular bone, as would be expected based 
on the changes observed in the trabecular bone of patients. Other bone abnormalities 
reported in EPM1 patients, e.g. scoliosis, arachnodactyly and accessory ossicles of 
the foot, are linked to skeletal growth (Suoranta et al. 2012). While no macroscopic 
morphological bone changes were identified in Cstb-/- mice, analysis of growthplate 
thickness from fixed and then decalcified hind limb sections revealed the growth plates 
in both the distal femurs and proximal tibias of the Cstb-/- mice to be significantly 
thinner compared to controls. The difference was observed both at the 1 and 4 months 
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timepoints (III, Figure 1). Still, even though Cstb-/- mice have been reported to 
weight less than healthy controls (Shannon et al. 2002), no difference in the length 
of the femur was observed (Cstb-/- 15.7 mm ± 0.17 vs. control 16.13 ±0.16, p=0.064). 
Possible causes for the observed changes in bone morphology were investigated 
in more detail from histological data. Counting the number of osteoclasts from 
sections of fixed and decalcified hind limb bone tissue revealed significantly decreased 
numbers of osteoclasts in Cstb-/- mice compared to controls. This difference was 
observed both at 1-and 4-months of age, in both the distal femurs and proximal 
tibias (III, Figure 2). Evaluation of the resorptive capacity of the osteoclast was 
done by quantifying immunohistochemical staining for TRACP 5b and cat K. This 
revealed higher expression of both TRACP 5b and sat K in the osteoclasts of Cstb-
/- mice, suggesting higher resorptive capacity per cell (III, Figure 2). As osteoblast 
cultures from Cstb-/- mice showed no indication of changes in cell morphology or 
function when compared to controls (data not shown), the findings imply that a 
reduced number of osteoclasts with possibly increased resorptive capacity are likely 
to contribute to the bone morphology changes associated with CSTB deficiency. The 
contribution of secondary factors to the observed skeletal changes in EPM1 patients 
has been previously discussed. Antiepileptic drugs, especially phenytoin, are known 
to cause calvarial thickening (Kattan 1970) and have previously been speculated to 
contribute to the bone changes in the EPM1 patients (Suoranta et al. 2012). Due to 
severe myoclonus, some EPM1 patients are also wheelchair bound. As immobility is 
known to affect bone structure and composition (Cervinka et al. 2011), the possible 
contribution of reduced mobility on bone findings in EPM1 patients has also been 
discussed (Suoranta et al. 2012). Nevertheless, the Cstb-/- mice showed changes in 
both trabecular bone structure and composition before the manifestation of ataxia 
at 6 months, so it is unlikely that immobility would contribute to the observed bone 
changes. The mice are also not subjected to any antiepileptic therapies and therefore 
the findings indicate that the bone changes in EPM1 patients are a direct result 
of deficient CSTB function resulting from changes in skeletal remodelling. Since 
skeletal changes do not appear to be a secondary phenomenon, they do not as such 
warrant changes in patient care e.g. modifying anti-epileptic medication.  
4.2.2 Impaired bone resorption in bone marrow derived Cstb-/ 
osteoclast cultures (III)
The findings from histology indicated that changes in osteoclast homeostasis could 
be responsible for the bone phenotype in Cstb-/- mice. The results suggest that 
changes in progenitor cell populations, cell viability, or apoptotic cell death of the 
osteoclasts may contribute to the observed bone changes. The possible changes in 
osteoclast function and homeostasis were therefore explored further in bone marrow 
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derived osteoclast cultures. Quantification of the cultures revealed a lower number 
of mature TRAP-positive multinucleated osteoclasts in the Cstb-/- cultures and 
the osteoclasts were also smaller compared to controls (III, Figure 3). Since both 
bone histology and osteoclast cultures indicated decreases in osteoclast numbers in 
Cstb-/- mice, the possible causes for this were investigated. First, a colorimetric assay 
was performed to study cell viability in the cultures, but no significant differences 
between the genotypes were observed (Cstb-/- 0.335 ± 0.007 absorbance units vs. 
control 0.328 ± 0.006 absorbance units; p=0.12), indicating that the viability of 
Cstb-/- osteoclasts is not compromised.
Next, the possible changes in precursor cell populations that could contribute to 
the observed osteoclast phenotype were investigated. Our previous studies have shown 
that the Cstb-/- mice exhibit early and severe microglial phenotype with microglial 
activation already at age P14 and increased chemokine release and chemotactic activity 
at P30 (Tegelberg et al. 2012, Okuneva et al. 2015). As microglia and osteoclasts 
share a common macrophage progenitor cell lineage, and multinuclear mature 
osteoclasts form through fusion of pre-osteoclastic cells, differences in macrophage 
progenitor population could translate into a smaller number of mature osteoclasts. 
Therefore possible changes in the composition of the progenitor cell population were 
investigated by performing flow cytometric analysis on bone marrow composition. 
The changes in the progenitor pool are however an unlikely cause for the decrease in 
osteoclast numbers since the number of macrophage precursors was actually slightly 
higher in the Cstb-/- mice (Cstb-/- 395 ± 56 cells per 100000 counted vs. control 247 
± 46 cells per 100000 counted; p=0.03). 
Third, we investigated the possible contribution of apoptotic cell death to 
the observed decrease in Cstb-/- osteoclast numbers. CSTB has been previously 
demonstrated to be capable of inhibiting osteoclast apoptosis and regulating bone 
resorption in vitro (Laitala-Leinonen et al. 2006). Furthermore, cathepsin K, which 
cystatin B inhibits has been shown to act as a modulator of osteoclastic apoptosis 
and senescence (Wilson et al. 2009, Chen et al. 2007). Therefore, cat K mediated 
osteoclastic apoptosis was investigated as a cause for the decrease in osteoclast 
numbers. Nonetheless, TUNEL staining did not show indications of apoptotic cell 
death in the cultures (III supplement, Figure 1). 
As the results would suggest that changes in progenitor cell numbers, cell viability 
or apoptotic cell death were not likely to contribute to the observed changes in 
osteoclast numbers, a qPCR-based gene expression profiling was performed from 
osteoclast cultures in order to determine if changes in the gene expression could 
implicate possible causes for the decrease in osteoclast numbers. The results of qPCR-
array illustrated moderate changes in genes related to cell growth, differentiation 
and resorptive function (III, Table 2, supplement Table 1). However, none of these 
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as such provided a direct explanation to the change in Cstb-/- osteoclast numbers. 
Bone morphogenic proteins (BMP) are a group of proteins known to promote 
osteoclast survival and differentiation (Okamoto et al. 2006, Wutzl et al. 2006, 
Itoh et al. 2001). In the array, BMPs were shown to be downregulated in the Cstb-
/- osteoclasts, with BMP3 downregulated 8-fold. Furthermore, activin A receptor 
1, which relays the signals from BMPs and is known to have an important role in 
osteoclast differentiation (Fuller, Bayley & Chambers 2000), was also downregulated 
1.5-fold. Genes connected with the resorptive function of the osteoclasts, such as 
matrix metallopeptidase 9 (MMP9), a protein playing an important role in bone 
remodelling (Ortega et al. 2003), was upregulated 4-fold and cat K 1.9-fold, the 
changes possibly reflecting compensatory mechanism in resorptive function due to 
smaller osteoclast numbers. Whether these changes simply reflect the phenotype 
of the osteoclast cultures, or are actually underlying causes responsible for the bone 
changes observed in the Cstb-/- mice, and probably in patients, remains unclear. 
Both the changes in gene expression and the quantification of staining intensity 
for TRACP 5b and cat K suggested elevated resorptive capacity in individual Cstb-
/- osteoclasts. A fluorescence based cat K assay was subsequently performed in 
osteoclast cultures but contrary to this hypothesis, the enzyme activity per well did 
not significantly differ between genotypes (Cstb-/- 0.97 vs. Control 1.00 fluorescence 
units). While in vitro results show no indication of elevated cat K activity, based on 
gene expression and immunohistochemistry data, enzymatic capacity for resorption 
in individual Cstb-/- osteoclasts might in fact be elevated compared to the controls, 
especially as CSTB has previously been shown to suppress osteoclastic resorption 
in vitro (Laitala-Leinonen et al. 2006).
We subsequently investigated whether the resorption capacity of Cstb-/- osteoclasts 
was indeed elevated compared to controls. The resorptive capacity was studied in vitro, 
by culturing osteoclasts in wells with synthetic bone coating. The experiment revealed 
that both the number and the area of the formed resorption pits was significantly 
decreased in the Cstb-/- osteoclast cultures (III, Figure 4). The results therefore suggest 
that even though the enzymatic resorptive capacity of the individual osteoclasts 
appears to be elevated, the overall resorptive capacity in the cultures is severely 
compromised, at least in vitro. The resorptive capacity is closely connected to both 
the cell number and cell size (Xing, Xiu & Boyce 2012). The lower overall resorption 
suggests that the higher resorptive capacity per cell is not able to overcome the effect 
of lower osteoclast number and size in the Cstb-/- group. It is also likely that the 
observed higher resorptive capacity per cell is, at least to some degree, a compensatory 
mechanism to the decrease in resorptive function. 
As resorption pit formation assay revealed decreased resorptive capacity in the 
Cstb-/- cultures, it is likely that the thicker trabeculae and more heavily mineralized 
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bone in Cstb-/- mice are an outcome of the deficient resorptive function caused by the 
decreased osteoclast number and size. Since the bone findings seen in patients are not 
likely to result from reduced mobility or anti-epileptic therapies, it is probable that 
the bone changes present in EPM1 are caused by changes in osteoclast function and 
homeostasis, parallel to the changes demonstrated in Cstb-/- mice. While the exact 
mechanism by which a lack of CSTB leads to the changes in osteoclast homeostasis 
remains undisclosed, the current results indicate the role of CSTB in bone goes well 
beyond cat K inhibition, a view supported by previous studies (Laitala-Leinonen 
et al. 2006). Furthermore, cells cultured from cat K deficient mice with 129/Sv 
background have been shown to lack normal apoptosis and cellular senescence, and 
in a pre-osteoclastic cell line, induced cat K expression led to premature cellular 
senescence (Chen et al. 2007). Therefore the contribution of premature, possibly cat 
K mediated, cellular senescence to observed changes in osteoclast homeostasis and 
function should be further investigated. 
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5 CONCLUSIONS
This thesis examined the progress and the background of the pathological changes 
in EPM1 in the brain and bone by utilizing advanced imaging methods and modern 
image analysis methodology in the mouse model of the disease. The in vivo MRI 
volumetry in Cstb-/- mice exposed spatiotemporally heterogeneous atrophy in that 
was demonstrated to be progressive and the findings in a longitudinal TBSS analysis 
revealed widespread and progressing WM damage with parallel development. As 
the TBSS results demonstrated high correspondence between the findings in the 
Cstb-/- mice and EPM1 patients, this suggested that patients also undergo similar 
axonal degeneration as demonstrated in the mouse model of the disease. The results 
showed disturbed thalamocortical connections and cerebellar damage that is likely 
to contribute to the observed disabling motor disturbances in EPM1. The extent 
of this damage also gives an indication of why the myoclonus in EPM1 remains 
resistant to treatment. The spatiotemporal order of subsequent pathological changes 
demonstrated in this study suggests that the WM pathologies in EPM1 could be 
secondary in the disease process, and thus possibly be avoided with early therapeutic 
interventions. Therefore future investigation must be aimed at the first stages of 
disease. As the earliest observed changes in Cstb-/- mice indicate altered microglial 
function, early therapies targeting the microglia in EPM1 should be investigated. 
The investigation of physiological changes underlying the bone phenotype in 
EPM1 revealed altered osteoclast function and homeostasis in the form of decreased 
resorptive capacity due to decrease in osteoclast numbers. While we were not able 
to discover the why a lack of CSTB leads to the observed changes, our results 
demonstrated that CSTB has a role in regulating bone metabolism beyond cat K 
inhibition. As the function of CSTB is still poorly understood, and a possible role 
in regulating osteoclast homeostasis could have therapeutic implications in disorders 
of the bone such as osteoporosis, the role of CSTB in bone metabolism should be 
studied further.
Finally, the research in this thesis was also able to introduce new methods for 
research in mouse models of neurodegenerative diseases in the form of longitudinal 
TBSS. While the methodology was demonstrated here in an ex vivo setting, with 
more advanced imaging systems and shorter imaging times, in vivo follow-up of 
animal models of neurodegenerative diseases can be achieved, enabling more elegant 
study settings in the future. 
The results shown in this thesis provided novel information about cellular and 
tissue level changes underlying the neuronal and bone pathologies in EPM1 and 
the high correlation between the mouse model and the findings in patients supplied 
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further affirmation for the use of the mouse model in EPM1 research. Ultimately, 
the results provided new insight both into the disease progression of EPM1 and the 
tissue level changes underlying the pathological changes present in the disease. As 
the background of these observed pathologies should in the future be investigated 
in depth, these findings raise the prospects for future research and highlight the 
continuity in the investigation of EPM1 pathogenesis.
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